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Abstract 
Malaria is one of the most pressing human health issues. Despite being an ancient disease, it 
is estimated to have an annual death rate of 445 000 with out of 216 million malaria related 
cases in 2016. Malaria is most widespread in developing regions of the world. Forty percent 
of the world’s population is exposed to varying degrees of malaria. Malaria is caused by 
different species of the Plasmodium genus and the disease is vector-borne. The disease may 
be cured if diagnosed early. Most drugs that were once effective in the treatment of malaria 
have become ineffective due to the emergence of resistance, which has become the main 
driving force behind efforts to discover and develop new drugs able to circumvent the 
resistance.  
Imidazopyridazines have been shown to have potent 
antiplasmodium activity. The lead compound MMV652103 
has been shown to display potent activity against the 
multidrug resistant K1 strain and the drug sensitive NF54 
strain of the human malaria parasite Plasmodium falciparum. 
However, the majority of the antimalarial imidazopyridazine compounds evaluated to date 
have solubility and off-target human ether-a-go-go-related gene (hERG) potassium ion 
channel liabilities.  
Towards improving solubility and de-risking the hERG liability, a series of analogues was 
designed and synthesised. Structure-Activity Relationship (SAR) and Structure-Property 
Relationship (SPR) studies aimed at retaining the good antiplasmodium activity while 
improving solubility and reducing hERG channel inhibition, were conducted. Previous 
studies conducted on this series of imidazopyridazines have shown that incorporation of 
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hydrogen bond donors or acceptors resulted in improving solubility and hERG channel 
inhibition. 
 While the lead compound MMV652103 at pH 6.5 has a sub-optimal solubility of 5 µM, all 
target compounds showed an improvement in solubility. Five analogues 59, 78, 84, 85, and 
86 exhibiting impressive in vitro asexual blood stage antiplasmodium potency (IC50 < 100 
nM) and aqueous solubility (> 200 µM) were identified from the study. The identified 
compounds also displayed good activity against the sexual late-stage gametocytes, the 
transmissible forms of the parasite.  
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Chapter one 
1.1 Malaria: History and introduction 
Malaria symptoms were first described by the Chinese in the book Nei Ching in 2700 BC.
1
 In 
the 4
th
 century, malaria affected the Greeks with its depopulating effects in rural and urban 
areas. In The compendium of Suśruta, it is documented that after getting bitten by certain 
insects, patients showed malarial symptoms.
1
 Before the discovery of the disease causing 
parasites by Antoni van Leeuwenhoe in 1676, Greeks were well aware of characteristic poor 
health, fever, and enlarged spleens for people who lived in marshy places.
2
 Indeed, malaria 
has ravaged humans spreading and claiming lives over many years. 
1.2 Epidemiology of malaria 
Today, malaria is most prevalent in developing countries and its transmission can vary from 
region to region depending on rainfall patterns, social and environmental factors, availability 
of health services, and malaria control activities.
3
 The intensity of malaria is mainly 
dependent on climatic conditions with some climates favouring transmission, reproduction 
and survival of mosquitoes (Figure 1). Malaria slows down economic growth in Africa 
costing more than 12 billion dollars every year.
4
 There is a strong relationship between 
malaria and poor developing countries, where malaria is rampant and the society prospers the 
least.
4,5
 The cost of malaria hinders development in many ways including diverting funds to 
medical costs, reduced population growth, absenteeism from work, saving and investments, 
and reduced worker productivity, as well as premature mortality.
5
 Countries that have 
managed to eradicate malaria have gained economic growth.
4 
According to the World Health Organization (WHO) world malaria report, 216 million 
malaria cases and 445000 malaria-related deaths were reported in 2016.
6
 The WHO reports 
that African region accounted for 90 and 91 % of the cases and deaths, respectively. A huge 
2 
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portion of over two thirds (70 %) of these deaths were reported in children under the age of 5 
years.
6
 
 
Figure 1: Geographic distribution of malaria (Source: https://www.undispatch.com/un-
content/uploads/2014/12/Screen-Shot-2014-12-09-at-10.05.48-AM.png). 
1.3 Aetiology of malaria 
1.3.1 Parasites responsible for causing malaria 
Malaria is a vector-borne disease, and in humans, it is caused by five species of Plasmodium, 
namely P. falciparum, P. ovale, P. malariae, P. vivax, and P. knowlesi.
7
 The symptoms 
associated with malaria include fever, chills, muscle aches, fatigue, vomiting and abdominal 
discomfort.
3
 When malaria has progressed to severe disease and the person remains 
untreated, death may result. Malaria deaths which are not caused by P. falciparum are rare.
3
  
3 
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1.3.2 Malaria parasite life cycle 
Malaria is transmitted by the bites of an infected female anopheles mosquito.
3,7
 The 
transmission of the parasite can also occur when infected blood is passed to a recipient 
through blood transfusion, sharing of needles, and congenital infection.
3
 
When an infected anopheles mosquito takes in a blood meal, it injects sporozoites into the 
human host, which are carried by the blood stream to the liver (Figure 2). At the liver stage, 
the sporozoites invade hepatocytes, where they mature into exoerythrocytic forms.
8
 There are 
two different developmental pathways for exoerythrocytic parasites: Its either the parasites 
develop into schizonts or dormant forms called hypnozoites.
9
 The hypnozoites are 
particularly known to develop in P. vivax and P. ovale infections.
9
 These dormant forms can 
reactivate and develop at any time after the initial infection.
10
 Fully matured schizonts 
develop into merozoites, which are released from the liver and enter the blood stream.
8
 The 
merozoites in the blood begin to invade red blood cells and transform into trophozoites, 
which reproduce quickly through asexual reproduction into schizonts. This erythrocytic 
infection cycle is repeated.
11
 The symptoms of malaria become visible during the breaking 
down of red blood cells by merozoites. As merozoites in the blood grow, they develop into 
male and female gametes, which are taken up by the mosquito when it takes in blood meal 
from an infected person.
7
 The male and female gametes intermix and form zygotes inside the 
mosquito stomach. The zygotes are elongated (ookinetes) and mobile. The ookinetes move 
into the midgut wall of the mosquito where they grow into oocysts. These oocysts then grow 
and rupture releasing sporozoites, which in turn move to the salivary glands and are released 
with saliva when a female anopheles mosquito takes in a blood meal from a human host.      
4 
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Figure 2: Malaria life cycle (Source:https://www.cdc.gov/malaria/about/disease.html). 
1.4 Malaria control, prevention and treatment           
1.4.1 Vector control 
Global interventions to decrease the spread of malaria and its impact have involved many 
strategies such as vector control, use of chemoprophylaxis, chemotherapy, bed nets, 
genetically modified sporozoites and use of insecticides.
3,7
 Strategies to control anopheles 
mosquitoes have limitations, for example, a limitation to the use of insecticides is that, the 
mosquito population that was exposed to the insecticide dies out and, once the insecticide is 
withdrawn, the mosquito population quickly grows back. Other methods such as sleeping 
under insecticide-treated nets (ITNs) and indoor residual spraying (IRS) have yielded good 
results. In this regard, using ITN and IRS has decreased child (under the age of 5 years) 
mortality rate by 55 %.
12,13
 The economic burden imposed by malaria has caused poor 
5 
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countries to discontinue the use of IRS and ITN because of limited funds. On the other hand, 
South Africa in particular continued to use IRS and ITN and has consequently achieved over 
80 % malaria eradication.
14
 It is difficult to kill a moving mosquito, but when their habitants 
are exposed to insecticide and larvicide, which will prevent egg nourishment leading to 
population decline as fewer mosquitoes are able to mature.
15
 Recent research conducted by 
Mueller et al, has resulted in the identification of a gene, UIS3, expressed in the pre-
erythrocytic stage of the malaria parasite life cycle and upregulated by infective sporozoites. 
It was demonstrated in vivo  that sporozoites which lacked the UIS3 gene provide complete 
protection in a rodent malaria model.
16
 In the studies, it was concluded that it is possible to 
have safe and effective genetically modified malaria parasites. 
1.4.2 Chemoprophylaxis 
Malaria is devastating during pregnancy as it increases the chances of transmission from the 
mother to the unborn child. In pregnant women, malaria infection can result in low birth 
weight for new born infants, stillborn babies, maternal anaemia and increased prenatal 
mortality.
17
 People traveling to places where malaria is prevalent are advised to take 
medicines for chemoprophylaxis prior to departure. Chemoprophylaxis is the use of 
antimalarial medicines to prevent the development of malaria. It is noteworthy that there is no 
antimalarial drug that provides 100 % protection, but when supplemented with personal 
protective measures chemoprophylatic antimalarials can be effective.  
Treatment taken depends on which area the person is travelling to, what type of species and 
which drug resistant strain is prevalent.
18
 Primaquine (1) and proguanil (2) are recommended 
as causal prophylactic drugs (Figure 3). Casual prophylactics stop the development of 
disease in the liver by inhibiting pre-erythrocytic schizogony. Casual prophylatics are not 
recommended for daily use. On the other hand, suppressive prophylactics are used to treat 
malaria caused by asexual blood stage parasites, which results in the presentation of clinical 
6 
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symptoms.
18
 Doxycycline (3) is taken by travellers to an area which has ongoing transmission 
and is taken 1–2 days before arriving to the malaria endemic region. Mefloquine (4) is used 
for long trips and offers the advantage of being taken less frequently, once a week, which 
makes it convenient for users to complete the course. Relapsed malaria from hypnozoites is 
treated with primaquine over two weeks. Sulfadoxine (5) and pyrimethamine (6) are associated 
with reduced antenatal parasitaemia, low birthweight outcomes, and reduced severe or 
moderate anaemia.
19,20
 For these reasons, the WHO recommended the use of sulfadoxine-
pyrimethamine as intermittent preventive treatment for malaria in pregnancy (IPTp) and 
seasonal malaria chemoprevention (SMC). Primaquine belongs to a class of the 8-
aminoquinolines and has been the only drug used to treat malaria relapse.
21
 The challenge 
with primaquine is that it requires 14 days of treatment and patients do not adhere to take 
treatment consistently and finish the course. Furthermore, primaquine induces haemolytic 
effects and is not recommended for patients with glucose-6-phosphate dehydrogenase 
(G6PD) deficiency.
21
 Recently, the United States Food and Drug Administration (FDA) has 
approved the use of tafenoquine (7) to cure P. vivax infections, which presents an improved 
alternative to primaquine.
22
 Tafenoquine offers an advantage over primaquine in that it is a 
single dose treatment.
23
 Although Tafenoquine has been approved by the FDA, it still retains 
haemolytic effects like primaquine and is not recommended for patients with G6PD 
defiency.
24
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Figure 3: Chemical Structures of drugs use for Chemoprophylaxis. 
1.4.3 Malaria vaccine 
Currently there is no commercially available vaccine approved for protection against malaria. 
However, there are more than 20 vaccines in development, others are being evaluated in 
clinical trials while others are in advanced preclinical development.
25
 The most advanced 
malaria vaccine is the RTS,S/AS01(RTS,S), which offers partial  protection against P. 
falciparum in children.
26 The RTS,S/AS01(RTS,S) vaccine is also known as Mosquirix and 
its route of administration is through injection. The vaccine is being evaluated in sub-Saharan 
Africa, and the WHO announced in April 2017 a partnership with Ghana, Kenya and Malawi 
to make RTS,S/AS01(RTS,S) available in selected areas of the three countries.
27
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1.4.4 Current treatment regimens and parasite resistance to antimalarial drugs 
Efforts to control malaria using currently available antimalarial drugs are becoming less 
effective because the malaria-causing parasite has developed varying degrees of resistance to 
drugs that are recommended as frontline treatments for malaria.
28
 Drugs such as chloroquine 
(12) in Figure 4 and sulfadoxine-pyrimethamine (Figure 3), which were once effective, are 
no longer in use because of widespread parasite resistance. Chloroquine offered one 
advantage as an antimalarial: it was cheaper and widely available.
3
 In the 1970s the Chinese 
discovered the antimalarial properties of artemisinin (8) with its other semi-synthetic 
derivatives artemether (10), artesunate (11), and dihydroartemisinin (9) (Figure 4).
29
 The 
WHO recommended in 2001 that short acting artemisinins should be used in combination 
with other long acting drugs (Artesunate (11)-Mefloquine (4), Artemether (10)-Lumefantrine 
(15), Artesunate (11)-Amodiaquine (13), Artesunate (11)-Sulfadoxine (5)-Pyrimethamine (6), 
and Dihydroartemisinin (9)-Piperaquine (14) in countries where P. falciparum had developed 
resistance to conventional antimalarial drugs.
29
 Since then, the mainstay of antimalarial 
chemotherapy are the so called artemisinin-based combination therapies (ACTs) (Figure 4).
30
 
Regrettably, in Western Cambodia, it has been reported that the efficacy of ACTs has 
diminished, a phenomenon attributed to the emergence of resistance against these important 
antimalarials.
31,32
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Figure 4: Structures of antimalarial drugs in clinical use. 
1.4.5 Categories of antimalarial drugs based on parasite life cycle targeted  
Understanding where the drug exerts its effect in the life cycle of the malaria parasite is 
important because it will require less effort to determine which drugs to use as partners in an 
attempt to delay the emergence of drug resistance.
33
 Antimalarials are divided into different 
classes, each class differs from other by chemical structure, their mechanism of action or both 
(Table 1).
33
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Table 1: Example of antimalarials from different classes. 
Class Molecule 
Endoperoxides Artemether (10) 
4-Aminoquinolines Amodiaquine (13) 
8-Aminoquinolines Primaquine (14) 
Antifolates Pyrimethamine (6) 
Sulfonamides Sulfadoxine (5) 
Antibiotics Azithromycin 
Amino alcohols  Lumefantrine (15) 
 
Cycloguanil, pyrimethamine, and atovaquone drugs have shown to be highly potent in 
transmission blocking from the mosquito to human host by killing schizont in the liver.
33
 In 
the same studies conducted by Delves et al, the endoperoxide OZ439 showed strong 
inhibition of gamete formation and gametocyte maturation.
33
  
1.5 Antimalarial drug pipeline   
Figure 5 shows selected drug candidates in clinical development. The advantage of the 
current antimalarial drug pipeline is that it is rich with molecules which have shown activity 
at different stages of the malaria parasite’s life cycle. In the current pipeline, combinations 
and single molecular entities (Tafenoquine, Artefenomel (OZ439)/ferroquine, 
KAF156/lumefantrine, Cipargamin, DSM265, MMV048, SJ733, P218, M5717, and 
AN13762) are able to block transmission from mosquito to the human host and others are 
providing chemoprotection.
34
 Within the compounds that are in development, two partner 
drugs (artefenomel (16) / ferroquine (17) and KAF156(18) / lumefantrine (15) have 
progressed to phase IIb clinical development.
34
  MMV048 (19) is a compound discovered by 
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an international team led by the University of Cape Town (UCT) Drug Discovery and 
Development centre, H3D.
35
 MMV048 (19) has potential to be used as a partner drug and 
could treat uncomplicated malaria in a single dose.
36
 
 
Figure 5: Selected compounds from the antimalarial drug candidate pipeline. 
1.6 Solubility in drug design and development 
1.6.1 Importance of solubility  
Solubility is a property of a substance (solute) that is able to dissolve in a solvent (liquid and 
gaseous) resulting in a homogenous system. The solubility of the same solute under different 
conditions can vary because of the effect of the surrounding environment such as 
temperature, pressure and pH of the solution.
37
 Saturation concentration is the concentration 
which cannot allow further dissolution of solute under specific conditions. Once the solution 
reaches saturation point, the solute will begin to precipitate out from the solution. For drugs, 
solubility is important because it influences how the drug must be administered to the patient, 
and influences absorption, distribution, metabolism and excretion (ADME).
38
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Drugs with poor aqueous solubility and low dissolution rates are associated with slow 
absorption, low bioavailability and gastrointestinal mucosal toxicity.
39
 For drugs that are 
orally administered, solubility is important since it is a limiting parameter for the 
concentration required for the desired pharmacological effect.
39
 Once administered, poorly 
soluble drugs may crystallize and cause acute toxicity.
40
 Moreover, low solubility has caused 
many failures in drug development. In a classic case of poor solubility, ritonavir used to treat 
HIV-1 infection, was introduced in 1996 but withdrawn from market in 1998 because of a 
lower energy, more stable polymorph (II) appeared, causing a slowed dissolution rate of the 
marketed dosage form and reducing the bioavailability of the drug.
41
 The equation that relates 
the solubility (M) of a compound with its melting point and lipophilicity (P) is as follows:  
Log[solubility (M)] = 0.5 – (log P) – 0.01{[melting point (°C)] – 25}. 
The solubility of a solute is described by the equation as a function of two variables. For a 
solid solute, solubility depends on its ability to interact with water and also on its 
crystallinity.
42
 Crystal packing and crystal lattice energy influences melting point. Disruption 
of crystal packing and crystal lattice energy will change the melting point and solubility.
43
 
LogP is the measure of interaction of the solute with water. 
1.6.2 Methods to measure solubility 
1.6.2.1 Kinetic and thermodynamic   
There are two methods (kinetic and thermodynamic) used to measure the solubility of a 
compound and both have their own advantages and drawbacks. Kinetic solubility is relatively 
easy to perform compared to thermodynamic solubility. Kinetic solubility answers the 
question: ―to what extent does the compound precipitate‖ while thermodynamic solubility 
answers the question: ―to what extent does the compound dissolve‖.44 In kinetic solubility, 
the compound is dissolved in a solvent in which it is freely soluble, for instance DMSO. 
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Aliquots of the DMSO solutions are then added to aqueous buffer to precipitate the 
compound.
44
 In thermodynamic solubility, the solid material is directly mixed in aqueous 
medium.
44
 The concentration of the compound in the supernatant is taken to be its solubility. 
Kinetic solubility has the following advantages. 
 Solubility results could be obtained within few hours. 
 Easy to handle samples (oily or solid) and since they are dissolved in DMSO, this cancels 
the effect of solid form differences. 
 Scientists are informed early to identify potential issues pertaining to poor absorption and 
bioassay result reliability.
45
 
 Enables medicinal chemists to deduce structure-solubility relationships.45  
Thermodynamic solubility has the following advantages. 
 Allows scientists to be able to determine the required formulation for development. 
 Allows scientists to plan a development strategy. 
 Important for file regulatory submission.  
Kinetic solubility values are relatively higher than thermodynamic ones, and with the ease 
associated with performing kinetic solubility, it is often used to give guidance on structure-
solubility relationships.
45
 Thermodynamic solubility is more accurate and its results are 
affected by the nature of the solid form. Chirality affects thermodynamic solubility because 
of the compound crystal form, e.g. S-ketoprofen (20) (Figure 6) and racemic RS-ketoprofen 
have different solubility values, 2.4 mg/L and 1.4 mg/L, respectively.
45
 Both solubility results 
are a measure of the concentration of the saturated aqueous phase, which could be either 
determined by HPLC- or UV-methods. A drawback of using the UV-method is that it is 
unable to detect impurities, compound degradation, starting material or by products from 
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synthesis.
44
 The HPLC-based method is time consuming, but offers the advantage of knowing 
the purity of the compound.   
 
Figure 6: S-Ketoprofen structure. 
1.6.2.2 Strategies to improve solubility  
Chemical approaches: In these approaches, a molecule is modified by incorporating 
molecular features, which have the potential to improve solubility. These modifications also 
have the potential to either compromise or improve activity. Examples of chemical 
modifications strategies include introduction of hydrogen bonding, ionisable groups, 
disruption of molecular planarity, reducing lipophilicity, and decreasing aromaticity. 
Figure 7 shows changes from parent compound to a derivative which incorporates amide and 
alcohol functional groups capable of forming H-bonds with water molecules.
46
 Functional 
groups in a molecule that can participate in hydrogen bonding interactions will contribute to 
the overall aqueous solubility and increase the hydrophilicity of a molecule.
38
 While adding 
more hydrogen bonding groups to a drug molecule may increase solubility, it is important to 
take into consideration the fact that hydrogen bonding groups may, sometimes, form 
intramolecular hydrogen bonds which may lead to decreased aqueous solubility.
38
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Figure 7: Examples of molecules with potential to form H-bonds.
46 
Figure 8 provides an example of a molecule with  an ionisable group that contributes to 
improved solubility.
46
 Compounds that contain ionisable groups such as amines or carboxylic 
acids, interact with water through ion-dipole interactions once protonated or deprotonated. 
The cation formed interacts with the electron rich site of the water dipole while the opposite 
is true for an anion.
38
 As ionisable groups are introduced into the drug molecule, the distance 
between the resulting two ionized unlike charges should be considered. If two oppositely 
charged groups are too close to each other, then intramolecular interactions are favoured 
thereby negatively impacting solubility.
38
 
 
Figure 8: Example of a molecule with ionisable group.
46
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Ishikawa and co-workers have demonstrated that disruption of molecular planarity and 
symmetry results in an increase in solubility, Figure 9. They employed the following 
strategies to disrupt molecular planarity: increasing the dihedral angle for biaryl systems, 
introducing a methyl substituent at the benzylic positions and twisting fused rings.
47
  
 
Figure 9: Example showing increase solubility by disrupting of molecular planarity or 
increase dihedral angle. 
Increasing the number of aromatic rings in a molecular structure causes a decrease in aqueous 
solubility (Figure 10).
48
 It is important to note that each ring counts as one even if it is from a 
fused ring system. The increased lattice energy, flatness of aromatic rings which allows 
greater π-stacking leads to reduced entropic contribution to the free energy of solvation.49 
 
Figure 10: Impact of reducing aromaticity to improve solubility. 
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Lipophilicity increases as the molecule gets larger and is detrimental to aqueous solubility.
50
 
Lipophilicity of an unbranched hydrocarbon chain is higher than that of a branched 
hydrocarbon chain as exemplified in Figure 11.
38
 
 
Figure 11: Example of a molecule with decreased lipophilicity. 
Incorporating polar or charged groups in a prodrug to improve aqueous solubility has also 
been used as a strategy. Figure 12 is an example of prodrug fosphenytoin (30), which is the 
prodrug of phenytoin (31).
45
 
 
Figure 12: Prodrug strategy to improve aqueous solubility. 
Physical approaches: These strategies including particle size reduction, solid depression are 
used to improve upon the solubility of drugs with the anticipation of not compromising the 
biological activity. However, with physical methods such as particle size reduction, 
molecules are likely to decompose/disintegrate due to mechanical stress.
51
 Solid dispersion is 
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another technique that can be applied to improve dissolution, absorption, and therapeutic 
efficacy.
51
 Other physical techniques to improve solubility include the use of super fluid 
processes, surfactants, solubilizers, cosolvency, hydrotrophy and novel excipients.
51
  
1.7 Drug induced cardiotoxicity  
1.7.1 The human ether-a go-go-related gene (hERG) K+ ion channel and its inhibition 
The human ether-a-go-go-related gene (hERG) K
+
 ion channel controls potassium current in 
the heart.
52
 The hERG channels are inside the heart and are responsible for coordinating the 
electrical activity of the heart, thus controlling the heartbeat. Undesirable drug interactions 
with the hERG channels can cause tachyarrhythmia (torsades depointes) which can lead to 
sudden cardiac death.
53
 This cardiac death is a consequence of the blockade of IKr current in 
the heart.
54,55
 Drug molecules that cause the blockade of IKr are associated with elongation of 
the QT interval in the electrocardiogram. A number of drugs have been reported to cause 
abnormal cardiac muscle repolarisation and have been withdrawn from the market. Examples 
of such drugs include ((32, astemizole),(33, sertindole), (44, grepafloxacin), and 
(35,terfenadine) (Figure 13).
52
 It is important to note that other hERG disorders are caused 
by mutations which may lead to long or short QT intervals.
56,57
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Figure 13: Drugs withdrawn from market because of hERG liability. 
1.7.2 Strategies to reduce hERG potency 
Compounds containing a basic nitrogen are likely to get protonated at physiological pH. The 
resulting ammonium cations can potentially interact with π-electrons of the aromatic residues 
inside the cavity of the hERG channel.
58
 Therefore, decreasing the basicity of the basic 
nitrogen can substantially decrease the proportion of drug molecules which get protonated at 
physiological pH. This may disrupt π-cation interactions with the hERG channel (examples in 
Figure 14).
52
 The presence of basic nitrogen is not the only pharmacophore necessary for 
hERG binding. The most contributing interactions to hERG activity are π-stacking and 
hydrophobic interactions between aromatic amino acid residues (F656 and 652) in the hERG 
channel and aromatic moieties in the drug molecule. Thus, it is important to consider 
strategies that decrease the lipophilicity of a compound. Structural changes, small or big, can 
disrupt these interactions and affect hERG liability. The structural changes could include 
introducing distal aryl rings, decreasing the flexibility of the molecule and incorporating 
20 
Luyanda Centani – MSc Thesis, Univeristy of Cape Town, 2018   
different stereochemistry. Incorporation of zwitterions in a molecular structure is also known 
to counteract hERG activity.
58
 Furthermore, increasing the polarity of a molecule has the 
potential to decrease hERG activity since lipophilic interactions get destabilized by such 
changes.
52 
 
Figure 14: Examples of strategies to reduce hERG activity. 
1.8 Imidazopyridazines 
1.8.1 Introduction and background 
Early stages of drug discovery programmes have discovered applications of 
imidazopyridazine-based compounds in different therapeutic areas as potential treatments for 
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diseases such genetic disorders, viral infections, and anxiety. In studies conducted by Sacchi 
and co-workers, it was demonstrated that imidazopyridazines possess anti-inflammatory, 
analgesic and ulcerogenic activities.
59
 Identified imidazopyridazines compound 43  and 44 in 
Figure 15 have been shown to inhibit key kinases including tropomyosin receptor kinase 
(TRK) and mammalian target of rapamycin (mTOR), which are drivers for growth, 
proliferation, survival, and differentiation of cancerous cells.
60,61
 Proviral integration site of 
moloney (Pim) murine leukaemia kinases are important for cell survival and cell reproduction 
including other cell functions such as signal transduction pathways.
62–64
 In studies conducted 
by Wurz et al, imidazopyridazine (42) with inhibitory effects on the Pim kinase with IC50 
values less than 10 nM was identified.
65
 Also, imidazopyridazines have demonstrated potent 
activity against picornaviruses (45) in studies conducted by Hamdouchi and co-workers.
66
  
 
Figure 15: Examples of imidazopyridazines with other biological activities. 
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1.8.2 Imidazopyridazines as antimalarial agents 
Imidazopyridazines have been recently reported to have activity against P. falciparum 
malaria parasites.
46,67,68
 Studies conducted by McNamara, and co-workers have reported a 
class of derivatives of imidazopyridazines related to compound 46 (Figure 16) which are 
able to inhibit any stage of intracellular development of the Plasmodium parasite. They have 
concluded that this class of molecules are able to exert their effect by inhibiting the 
interaction of the natural substrate with the adenosine triphosphate (ATP)-binding pocket of 
phosphatidylinositol-4-OH kinase (PI(4)K).
68
 Bendjeddou and co-workers have synthesized a 
series of imidazopyridazines to target inhibition of eukaryotic kinases, including mammalian 
and protozoan kinases.
69
 In this study, it was found that imidazopyridazine derivatives 
exemplified by compound 47 (Figure 16) showed potent inhibition of P. falciparum cyclin-
dependent kinase-like kinase 1 (PfCLK1).
69
 A target-based screening of imidazopyridazines 
conducted by Judith and co-workers identified  a class of compounds exemplified by 
compound 48 (Figure 16), which kills the parasite at two different stages, the late schizogony 
stage and trophozoite stage.
70
 These imidazopyridazines break the life cycle of the parasite by 
inhibiting cyclic guanosine monophosphate (cGMP)-dependent protein kinase (PKG) and 
small heat shock protein (HSP29).
70
 P. falciparum calcium-dependent protein kinase 1 
(PfCDPK1) plays a crucial role in the life-cycle of the parasite. It is critical when the parasite 
invades red blood cells and is responsible for its motility.
71,72
 In this regard, structure-activity 
relationships (SAR) conducted by Chapman and co-workers on a series of 
imidazopyridazines show selective and potent inhibition of PfCDPK1.
73
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Figure 16: Selected imidazopyridazines which are kinase inhibitors of P.f kinases. 
In studies performed by Le Manach, et al, antimalarial imidazopyridazines were discovered 
through whole cell high throughput screening (HTS) of a SoftFocus library. In a sub-library 
named SFK52 and 488 diaryl-imidazopyridazines hits were identified (Figure 17).
67
 Hit 
compounds that showed potency at a screening concentration of 1.82 µM were selected and 
resynthesized. The compounds were tested for activity against the sensitive (NF54) and 
resistant (K1) strains of P. falciparum and compounds showing potency (IC50) between 15 
nM to 25 nM were identified. The three hit compounds displayed undesirable in vitro ADME 
properties, and were also found to have high human hepatic extraction ratio (EH) > 0.8.  
Compounds 49 and 50 were chosen as starting points for medicinal chemistry optimization. 
The optimization of potency through SAR led to the discovery of the lead compound 
(MMV652103) shown in Figure 17. However, this compound was characterized by poor 
solubility at pH 6.5 (< 5 µM) although slight improvement was observed under acidic 
conditions.
46
 Moreover, the lead compound showed a hERG (IC50 = 0.9 µM) inhibition 
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liability. In an attempt to increase solubility and de-risk hERG binding, Le Manach, et al., 
synthesized analogues with decreased lipophilicity by replacing phenyl rings with pyridyl 
rings after which the compounds showed weakly improved solubility. Solubility was also 
found to substantially improve after introducing substituents containing amide groups and 
other water solubilising H-bonding groups. Some analogues also displayed high solubility (> 
100 μM) while maintaining high activity against the PfNF54 strain (IC50 < 35 nM). Solubility 
was also found to increase when the sulfones was substituted with sulfoxides, which are 
strongly involved in hydrogen bonding compared to the former and led to the discovery of 
compound 52 which showed improved solubility and improved in vivo efficacy. Selected 
compounds, which were evaluated for hERG inhibition were found to be highly potent on 
this channel with IC50 containing value of 0.3-0.4 µM.  
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HTS
 
Figure 17: General structure of hit compounds identified from an SKF52 sub-library and the 
lead compound 52 resulting from medicinal chemistry optimization. 
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1.9 Research programme 
1.9.1 Study justification 
Naturally, parasites evolve. This evolution has led to the development of resistance to many 
once effective antimalarials such as chloroquine and sulfadoxine-pyrimethamine as already 
described in the introduction part of this dissertation.
74
 Recently, emerging resistance to the 
current frontline treatment option, the ACTs, has been reported on the Thai-Cambodia 
boarder and Vietnam.
75,76
 Additionally, resistance to amodiaquine, one of the partner drugs in 
ACTs has been reported in South America, Asia and East Africa.
77
 The parasite’s resistance 
to available drugs necessitates efforts to find new drugs with a different mechanism of action. 
Furthermore, antimalarials with multistage activity on different stages of parasite 
development are needed. These could potentially offer prophylaxis, block transmission, 
prevent relapse and relieve clinical symptoms. The search for new antimalarials is also 
motivated by the need to find medicines that could cure malaria in a single dose thereby 
avoiding patient compliance issues associated with prolonged multiple dosing regimens.
9
  
Imidazopridazines have shown diverse range of pharmacological properties and, are 
structurally novel compared to clinically used antimalarials. As already mentioned, studies 
conducted by Le Manach et al, have identified imidazopyridazine compounds with potent 
antiplasmodium activity but with liabilities, including strong off target activities such as 
hERG inhibition and poor aqueous solubility.
46,67
 This project was designed to address the 
poor aqueous solubility and cardiotoxicity risk that could arise from hERG inhibition of 
imidazopyridazine compounds identified by Le Manach et al. 
1.9.2 Research hypothesis  
The research question is whether it will be possible to identify imidazopyridazine-based 
antimalarial drug leads with favourable solubility and hERG properties. 
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1.9.3 Objective  
To optimise the solubility and cardiotoxicity risk profile of antimalarial imidazopyridazines. 
1.9.4 Specific aims 
i) Synthesis and characterization of antimalarial imidazopyridazines designed to 
improve solubility and hERG inhibition profiles.  
ii) Profiling of synthesized compounds with respect to antiplasmodium activity 
and solubility. 
iii) Derivation of antiplasmodium structure-activity relationship (SAR) as well as 
solubility structure property relationship (SPR) profiles. 
iv) Investigation of factors (e.g. melting point, calculated dihedral angle by single 
X-ray and/or Density Functional Theory calculations, CLogP, and retention 
time on reversed-phase HPLC) affecting solubility and deduce relationships. 
v) Submission of the selected frontrunner compounds with potent 
antiplasmodium activity for cytotoxicity and hERG profiling. 
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Chapter Two 
2.1 Introduction 
This chapter describes the design, synthesis and spectroscopic characterisation of 
imidazopyridazine analogues. Figure 18 shows the core scaffold of imidazopyridazines. 
Previous studies conducted by Le Manach, et al have identified substituent positions around 
the core-scaffold which are optimal for potent antiplasmodium activity.
67
 In this regard, a 
series of compounds were synthesized to further expand the SAR at positions 3 and 6 of the 
scaffold. 
1
H-NMR, 
13
C-NMR, Correlation Spectroscopy (COSY), Heteronuclear Single 
Quantum Coherence (HSQC) spectra and LCMS were used to confirm the molecular 
structure. LCMS was also used to determine purity. 
 
Figure 18: Imidazopyridazine core scaffold. 
2.2 Rationale and design  
Target compounds were designed with structural modifications aimed at improving 
solubility, and decreasing hERG channel inhibition activity while potentially retaining and/or 
improving good antiplasmodium activity. 
In their previous studies, Le Manach and co-workers, reported imidazopyridazine-derived 
analogues that are meta-substituted on the phenyl ring at position R2 (Figure 19), which 
retained good antiplasmodium activity. Where the meta-substituent was a sulfoxide, 
solubility was also improved.
46
 Based on these observations, a meta-substituted phenyl ring 
with a sulfoxide group at position R2 was fixed, while making modifications on the right hand 
side (RHS) of the molecule. On the RHS portion at R1, amide functionalities at the para 
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position of the phenyl ring were incorporated. This was guided by prior SAR findings by Le 
Manach and co-workers who established that the para position on the RHS phenyl ring was 
optimal for potency. Introduction of the amide functionality was also inspired by the need to 
introduce hydrogen bonding groups to potentially enhance solubility by forming hydrogen 
bonding interactions with water molecules.
46
 It was also observed previously that compounds 
containing amide bonds had reduced hERG inhibition activity.
46
 
 
Figure 19: Diarylated imidazopyridazine scaffold showing a fixed substistuent R2 and point 
of derivatization R1. 
In this project, an array of different amido compounds was proposed for synthesis in order to 
expand the scope of SAR studies (Figure 20). Such (amide bond) water solubilizing 
molecular features in the proposed compounds would be expected not only to improve water 
solubility but potentially discourage lipophilic drug-hERG binding interactions. In addition, 
some polar analogues 57, 58, 60, 62, 66, 67, 68, 69, and 70 incorporated additional water 
solubilising groups on the amidated side chain and ring. The sulfoxide version of analogue 74 
has been found to be highly potent (NF54: IC50 < 50 nM) in recent work (unpublished data). 
In this regard, the sulfone was synthesized since sulfoxides are expected to be converted to 
sulfones in vivo. 
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Figure 20: Analogues synthesized for Series 1 studies. MW, molecular weight (g/mol); 
tPSA, total polar surface area (Å
2
); cLogP, calculated partion coefficient. 
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The results from Series 1 were used as a guide towards structural modifications executed in 
Series 2 (Figure 21). In this regard, structural modifications from Series 1 that preserve 
potent antiplasmodium activity, lower hERG activity and improved solubility were 
implemented in the next generation analogues of Series 2.  
 
Figure 21: Analogues synthesized for Series 2 studies. MW, molecular weight (g/mol); 
tPSA, total polar surface area (Å
2
); cLogP, calculated partion coefficient. 
32 
Luyanda Centani – MSc Thesis, Univeristy of Cape Town, 2018   
2.3 Chemistry for Series 1 
Intermediate 53 was prepared by a condensation/cyclization reaction of commercially 
available 3-amino-6-chloropyridazine with bromoacetaldehyde diethyl acetal in the presence 
of aqueous HBr (Scheme 1).
67
 A regioselective iodination was performed with N-
iodosuccinimide (NIS) to give 54 in good yield. The iodinated compound was then subjected 
to a regioselective Suzuki-Miyaura coupling reaction with 4-carboxyphenylboronic acid to 
afford 55 in moderate yield. A second Suzuki-Miyaura reaction with (3-
(methylsulfinyl)phenyl)boronic acid gave the sulfoxide-substituted intermediate 56 in 
reasonable yield.
67
 A final acid catalyzed amide coupling step in the presence of 
propylphosphonic anhydride (T3P) to give the target compounds for Series 1.  
The sulfone-deravative analogue 74 was synthesized via a different intermediate 73 in 
Scheme 2. Where the chloro-substituted pyridazine intermediate 53 was subjected to a 
Suzuki-Miyaura reaction with (3-(methylsulfonyl)phenyl)boronic acid to obtain the 
intermediate 71, which was then iodinated in the presence of NIS to give 72 in good yield. A 
second Suzuki-Miyaura coupling on this intermediate then delivered the benzoic acid 
intermediate 73 in low yield. An amide coupling in the presence of T3P gave 74 in poor 
yield. The final target compounds with their respective yields are summarised in Table 2.  
 
33 
Luyanda Centani – MSc Thesis, Univeristy of Cape Town, 2018   
 
Scheme 1: Synthetic scheme for the synthesis of amidated imidazopyridazine analogues 57–70: Reagents and 
conditions (i) BrCH2CCH(OEt)2, HBr, EtOH/H2O, 103 °C , 16 h; (ii) NIS, DMF, 30 °C, 6 days; (iii) 4-
carboxyphenylboronic acid, Pd(PPh3)2Cl2, 1M K2CO3, DMF, 80 °C, 12 h; (iv)  3-methylsulfinylphenylboronic 
acid, Pd(PPh3)2Cl2, 1M K2CO3, DMF, 100 °C, 16 h; (v) appropriate amine or amine hydrochloride salt, 50 % 
T3P in EtOAc, DIPEA, DMF, 0–50 °C, 3–16 h;  
 
Scheme 2: Synthetic scheme for the synthesis of amidated imidazopyridazine analogue 74: Reagents and 
conditions (i)  3-methylsulfonylphenylboronic acid, Pd(PPh3)2Cl2, 1M K2CO3, DMF, 100 °C, 19 h; (ii) NIS, 
DMF, 35 °C, 3 days; (iii) 4-carboxyphenylboronic acid, Pd(PPh3)2Cl2, 1M K2CO3, DMF, 80 °C, 15 h; (iv) 
methyl amine hydrochloride salt 50 % T3P in EtOAc, DIPEA, DMF, 50 °C, 3 h. 
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Table 2: Series 1 derivatives with respective % yields. 
 
Compound code R2 R1 Yield (%) 
56 SOMe 
 
59 
57 SOMe 
 
13 
58 SOMe 
 
 69  
59 SOMe 
 
14 
60 SOMe 
 
38 
61 SOMe 
 
43 
62 SOMe 
 
40 
63 SOMe 
 
40 
64 SOMe 
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65 SOMe 
 
27 
66 SOMe 
 
47 
67 SOMe 
 
13 
68 SOMe 
 
20 
69 SOMe 
 
9 
70 SOMe 
 
5 
74 SO2Me 
 
17 
 
 
2.3.1 
1
H-NMR, 
13
C-NMR interpretation 
The one-dimensional 
1
H-NMR and 
13
C-NMR spectra were processed using MestReNova 
v10.0.2-15465. Multiplicity patterns are reported using the following abbreviations s = 
singlet, d = doublet, t = triplet, m = multiplet, dd = doublet of doublets, br s = broad singlet, 
br m = broad multiplet, t = triplet, dt = doublet of triplets, dq = doublet of quartet. Coupling 
constants (J values) are reported in Hertz (Hz). Where assignment of 
1
H-NMR and 
13
C-NMR 
signals was ambiguous, two-dimensional NMR spectra from COSY, and HSQC spectroscopy 
were acquired to facilitate accurate assignments. The Attached Proton Test (APT) was 
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employed to identify negative and positive carbons. All final compounds were subjected to 
purity check experiments using LC-MS to ensure an acceptable level of purity (≥ 95%). 
2.3.2 Mechanism and characterisation for the cyclization of bromoacetaldehyde diethyl 
acetal with 6-chloropyridazin-3-amine (Step I, Scheme 1) 
The reaction mechanism involved in the generation of intermediate 53 begins with 
protonation of bromoacetaldehyde diethyl acetal by a Brønsted acid to produce a resonance-
stabilized oxonium ion with elimination of EtOH (Scheme 3).
78
 The stabilized oxonium ion 
is attacked by a water molecule whereafter intramolecular proton transfer and loss of EtOH 
leads to the formation of the protonated aldehyde. A nucleophilic addition of 6-
chloropyridazin-3-amine to the protonated aldehyde then affords a hydroxyl intermediate 
which upon intramolecular proton transfer undergoes elimination of water to form an 
iminium ion intermediate, which is then converted to the corresponding imine intermediate 
upon deprotonation by the water molecule. An intramolecular attack by the pyridazine 
nitrogen onto the alkyl bromide then leads to a cyclized intermediate from which water 
abstracts a proton leading to the aromatized product 53.  
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Scheme 3: Mechanism for the formation of the intermediate 53 from 6-chloropyridazin-3-
amine in the presence of HBr. 
The structure of intermediate 53 was confirmed by 
1
H-NMR spectroscopy as shown in 
Figure 22.I. A broad peak at δ 8.12–8.10 ppm was assigned to H7, which integrates for 1H. 
Typically this broad peak is observed as a doublet. However, due to the sensitivity of the 
NMR instrument, peak broadening was observed, resulting in the doublet coalescing to form 
a broad peak. Two doublets resonating at 8.02 ppm (J = 9.5 Hz) and 7.78 ppm (J = 1.3 Hz) 
integrating for 1H each were assigned to H6 and H8, respectively. Lastly, a relatively 
shielded doublet integrating for 1H, was observed at 7.28 ppm with a J-value of 9.5 Hz and 
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was assigned to the aromatic proton H1. Six carbon peaks in the 
13
C-NMR spectrum of 53 
were observed (Figure 22.II) and an LC-MS of the pseudomolecular ion was observed at m/z 
[M + H]
+
 = 154.1 shown in Figure 22.III.   
 
Figure 22.I: 
1
H-NMR spectrum of 53 at 300 MHz in methanol-d4. 
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Figure 22.II: 
13
C-NMR spectrum of 53 at 300 MHz in DMSO-d6. 
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Figure 22.III: LC-SM chromatogram of compound 53. 
2.3.3 Mechanism and characterisation for the iodination of 53 (Step II, Scheme 1) 
Iodination of intermediate 53 was regiospecific with only the most nucleophilic carbon being 
iodinated.
79
 NIS was used as a source of electrophilic iodine, whilst the electron rich π-bond 
from the five-membered ring in compound 53 acted as the nucleophile (Scheme 4). 
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Iodination on the six-membered ring of 53 is not possible as the carbons on this ring are less 
nucleophilic compared to the carbons on the five-membered ring. The second carbon in the 
five-membered ring does not undergo iodination because electrophilic attack at this carbon 
would lead to an unstable arenium intermediate with highly unstable resonance contributors. 
 
Scheme 4: The mechanism of reaction for the formation of 54 in the presence of NIS. 
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Successful iodination of compound 53 to obtain compound 54 was confirmed by 
1
H-NMR 
spectroscopy. The 
1
H-NMR spectrum (Figure 23) shows the iodinated product 54 with the 
disappearance of a doublet and appearance of a new singlet peak in the aromatic region. A 
singlet was observed at 7.87 ppm, integrating for 1H and was assigned to H8. The two 
doublets at 8.02 (J = 9.5 Hz) and 7.34 (J = 9.5 Hz) ppm were assigned to H6 and H1, 
respectively. Five carbon peaks in the 
13
C-NMR spectrum of 54 were observed, and on LC-
MS, a pseudomolecular mass ion was observed at m/z [M + H]
+
 = 279.7. 
 
Figure 23: 
1
H-NMR spectrum of 54 at 300 MHz, in methanol-d4. 
2.3.4 Mechanism and characterisation for formation of compound 55 (Step III, Scheme 
1) 
The Suzuki-Miyaura cross coupling reaction mechanism is shown in Scheme 5. Suzuki-
Miyaura reactions are highly regioselective and this selectivity depends on the nature of the 
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carbon-halogen bond strength.
78,80
 The carbon-halogen bond strength tends to decrease down 
the halogen group in the periodic table and this effect makes oxidative addition (first step in 
the catalytic cycle) difficult for the chlorine while iodine undergoes oxidative addition 
relatively easily.
80
 The halogen-carbon bond strength decreases down the group hence the 
carbon-iodo bond requires less energy for oxidative addition to occur compared to the 
carbon-chloro bond, which requires high temperature reaction conditions for oxidative 
addition to occur. Hence, the reaction for the substitution of chloro was carried out at a much 
higher temperature of 100 °C (in the preparation of 56) while iodine substitution was carried 
out at 80 °C (in the preparation of 55). In the first step, oxidative addition of the iodo-derived 
substrate 54, generates a palladium (II) intermediate. The second step of the catalytic cycle is 
transmetalation which is known to be slow, hence the base (K2CO3) was used to speed up this 
step.
78
 The ligands around the Pd(II) complex then rearrange into a cis orientation for 
reductive elimination to occur which regenerates the palladium (0) catalyst. 
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Scheme 5: Catalytic cycle of the Suzuki-Miyaura coupling reaction catalysed by 
PdCl2(PPh3)2. 
The successful formation of compound 55 was confirmed by 
1
H-NMR spectroscopy. As 
shown in Figure 24, 5 peaks in the aromatic region were observed in the 
1
H-NMR spectrum 
of 55. A sharp singlet at δ 8.43 ppm was assigned to proton H8 and integrates for 1H. A 
relatively deshielded doublet arising at 8.32 ppm (J = 9.4 Hz) integrating for 1H was assigned 
to H6. A doublet appearing at 8.23 ppm (J = 8.8 Hz) and integrating for 2H was assigned to 
H12 and H14. A second doublet resonating at 8.08 ppm (J = 8.8 Hz) and integrating for 2H 
was assigned to H11 and H15. A doublet assigned to H1 and appearing at 7.46 ppm (J = 9.5 
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Hz) integrated for 1H. Eleven carbon peaks in the 
13
C-NMR spectrum were observed while a 
pseudomolecular mass ion m/z [M + H]
+
 = 273.87 was observed on LC-MS. 
 
Figure 24: 
1
H-NMR spectrum of 55 at 600 MHz in DMSO-d6. 
2.3.5 Characterisation of the sulfoxide common intermediate 56 (Step IV, Scheme 1) 
The sulfoxide-substituted common intermediate 56 was obtained through a Suzuki-Miyaura 
cross coupling reaction. The 
1
H-NMR spectrum is shown in Figure 25. Focusing on the left-
hand side portion of the molecule, a triplet at 7.81 ppm (J = 7.7 Hz) was assigned to H13 and 
integrates for 1H. A multiplet at 8.36–8.29 ppm which integrates for 3H was assigned to H6, 
H8 and H12. A doublet signal at 7.96 ppm (J = 9.5 Hz), which was assigned to H1 integrates 
for 1H. A sharp singlet at 2.86 ppm, which integrates to 3H was assigned to H27. A triplet at 
8.43 ppm (1.8 Hz) was assigned to H16 and integrates for 1H. Two doublets of an AB spin 
system are observed at 8.18 (J = 8.4 Hz) and 8.05 (J = 8.3 Hz) ppm with each doublet 
integrating for 2H, attributed to H18, H20 and H17, H21, respectively. A doublet of triplet 
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resonating at 7.87 ppm (J = 6.8, 1.2 Hz) and integrates for 1H was assigned to H14.  Overall, 
17 peaks in the 
13
C-NMR spectrum were observed with some carbons co-resonating at the 
same chemical shift. LC-MS analysis revealed a pseudomolecular ion mass m/z [M + H]
+
 = 
377.8. 
 
Figure 25: 
1
H-NMR spectrum of 56 at 600 MHz in DMSO-d6. 
2.3.6 Characterisation of the sulfone-substitued intermediate 71 (Step I, Scheme 2) 
Intermediate 53 was subjected to a Suzuki-Miyaura cross coupling reaction with [3-
(methylsulfonyl)phenyl]boronic acid to afford compound 71. The 
1
H-NMR spectrum of 71 is 
shown in Figure 26. A triplet observed at 8.54 ppm (J = 1.9 Hz) was assigned to H15 and 
integrates for 1H. The H15 triplet is caused by long range coupling with H11 and H13. A 
multiplet at 8.41–8.35 ppm, which integrates for 2H was observed and was assigned to H8 
and H11. A doublet resonating at 8.23 ppm (J = 9.5 Hz) was assigned to H6 and integrates 
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for 1H. A doublet of triplets at 8.07 ppm (J = 12.9, 1.2 Hz) was assigned to H13, which 
integrates for 1H. A doublet observed at 7.88 ppm (J = 9.8 Hz) which integrates for 1H was 
assigned to H1. A multiplet at 7.8–7.81 ppm was assigned to H12 and H7 which integrates 
for 2H. A sharp singlet at 3.29 ppm integrating for 3H was assigned to H18. The intermediate 
was further confirmed by LC-MS which showed a pseudomolecular ion at, m/z [M+H]
+
 = 
273.9. 13 distinct peaks in the 
13-
C-NMR spectrum attributable to the 13 carbons in the 
structure were observed. 
 
Figure 26: 
1
H-NMR spectrum of 71 at 400 MHz in DMSO-d6. 
2.3.7 Characterisation of 72  intermediate (Step II, Scheme 2) 
The intermediate 71 was iodinated with NIS to afford compound 72. The 
1
H-NMR spectrum 
(Figure 27) of 72 shows a triplet at 8.65 ppm (J = 1.9 Hz) integrating for H1 which was 
assigned to H15. A doublet of triplets integrating for H1 at 8.48 ppm (J = 7.9, 1.8 Hz) was 
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assigned to H11. A doublet resonating at 8.29 ppm (J = 9.5 Hz) was assigned to H6 and 
integrates for 1H. A doublet of triplets observed at 8.13 ppm (J = 7.8, 1.8 Hz), which 
integrates for 1H was assigned to H13. A multiplet signal at 8.03–7.97 ppm, which integrates 
for 2H was assigned to H8 and H1. A triplet observed at 7.90 ppm (J = 7.9 Hz), which 
integrates for 1H, was assigned to H12. A sharp singlet at 3.34 ppm was assigned to H18 and 
integrates for 3H. Furthermore, a pseudomolecular ion, m/z [M+H]
+
 = 399.6, for this 
intermediate was observed upon LC-MS analysis while 13 peaks in the 
13
C-NMR spectrum 
were observed which corresponded to the 13 carbons of this intermediate.   
 
Figure 27: 
1-
H-NMR spectrum of 72 at 400 MHz in DMSO-d6. 
2.3.8 Characterisation of intermediate 73 (Step III, Scheme 2) 
The sulfone compound 73 was synthesized by coupling 4-carboxyphenylboronic acid with 
the intermediate 72 through a Suzuki-Miyaura cross coupling reaction. The 
1
H-NMR 
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spectrum of 73 is shown in Figure 28. The introduction of the 4-carboxyphenyl group was 
accompanied by the appearance of extra signals in the spectrum. A doublet observed at 8.34 
ppm (J = 8.7 Hz), which integrates for 2H was assigned to H22 and H24. A doublet at 8.09 
ppm (J = 8.3 Hz), which integrates for 2H was assigned to H21 and H25. A triplet integrating 
for 1H observed at 8.67 ppm (J = 1.8 Hz) was assigned to H15. A doublet of triplets at 8.52 
ppm (J = 7.9, 1.9 Hz) was assigned to H11 and integrates for 1H. A singlet at 8.43 ppm, 
which integrates for 1H was assigned to H8. A doublet resonating at 8.40 ppm (J = 9.5 Hz) 
was assigned to H6 and integrates for 1H. A doublet of triplets, which integrates for 1H, was 
observed at 8.12 ppm (J = 7.8, 1.9 Hz) was assigned to H13. The doublet observed at 8.05 
ppm (J = 9.6 Hz) and integrates for 1H was assigned to H1. A triplet observed at 7.91 ppm (J 
= 7.9 Hz) integrating for 1H was assigned to H12. Lastly, a sharp singlet at 3.35 ppm was 
assigned to H19 and integrates for 3H. When subjected to further analysis by LC-MS, 73 
exhibited a pseudomolecular ion (ESI/APCI: m/z [M+H]
 +
 = 393.8). Additionally, 17 peaks in 
the 
13
C-NMR spectrum with some carbons co-resonating at the same chemical shift.   
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Figure 28:
1
H-NMR spectrum of 73 at 600 MHz in DMSO-d6. 
2.3.9 Mechanism for formation, and characterisation, of final amide target compounds 
(Step V in Scheme 1 and Step IV Scheme 2) 
In the first step of the mechanism, DIPEA depronate the acidic proton of the carboxylic acid 
to form a carboxylate ion (Scheme 6). The carboxylate ion then attacks the phosphorus atom 
of T3P in the second step. The intermediate formed now contains a good leaving group. The 
primary or secondary amine then attacks the carbonyl carbon to expel the T3P moiety 
resulting in the target compound after protonation. 
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Scheme 6: Mechanism of T3P-mediated acid-amine coupling. 
The 
1
H-NMR spectrum of target compound 59 is shown in Figure 29.I. The proton H15 was 
assigned to a peak appearing as a triplet at δ 8.41 ppm (J = 1.8 Hz), which integrates for 1H. 
The relatively small J-value indicates long range coupling with H11 and H13. The two 
doublets observed at 8.26 (J = 8.6 Hz) and 7.98 (J = 8.5 Hz) ppm each integrating for 2H 
were assigned to H19, H21 and H18, H22, respectively. A doublet of triplets resonating at 
8.23 ppm (J = 5.2, 1.3 Hz) was assigned to H11 which integrates for 1H. A singlet at 8.18 
ppm was assigned to H8 and integrates for 1H. A doublet at 8.13 ppm (J = 9.5 Hz) which 
integrates for 1H was assigned to H6. A multiplet arising at 7.86–7.81 ppm and integrating 
for 2H was assigned to H1 and H13. A triplet observed at 7.75 ppm (J = 7.9 Hz) was 
assigned to H12 and integrates for 1H. A doublet of doublets of triplets at 6.00 ppm (J = 17.2, 
10.3, 5.6 Hz) was assigned to H33 and integrates for 1H. Two doublet of quartet signals at 
5.30 and 5.18 ppm were assigned to two geminal protons H31 and H32, respectively. H31 is 
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trans to H33 and has a larger J-value of 17.2 Hz and is more deshielded relative to H32. On 
the other hand, H32 is cis to H33 and has a lower J-value of 10.3 Hz. H28 was assigned to a 
doublet of triplet (J = 5.6, 1.7 Hz) at 4.06 ppm and integrates for 2H. A sharp singlet in the 
aliphatic region was assigned to H27 and integrates for 3H. In Figure 29.II and Figure 29.III 
are COSY spectra of 59, which were used to identify protons that are corelating. The solid 
black lines in COSY spectra of 59 indicate protons that are correlating.  In the MS 
chromatogram (Figure 29.IV), acquired by LC-MS, ESI/APCI, an m/z value of 416.8 
corresponding to pseudomolecular ion [M+H]
+
 of the target compound was observed. 
Additionally, the 
13
C-NMR spectrum showed 21 distinct signals attributable to the 23 carbons 
of the compound as shown in Figure 29.V. Carbons (C18, C22,) and (C19, C21) are co-
resonating at the same chemical shifts as indicated in Figure 29.V. The asterics in the carbon 
spectrum indicates carbons that do not have protons attached and double asteric indicates a 
carbonyl carbon, which resonates at 167.97 ppm. Figure 29.VI is HSQC spectrum of 59, 
which was used to match proton to its carbon.   
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Figure 29.I: 
1
H-NMR spectrum of 59 at 600 MHz in Methanol-d4. 
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Figure 29.II: COSY spectrum of 59 aromatic regions downfield at 600 MHz in Methanol-d4. 
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Figure 29.III: COSY spectrum of 59 upfield aliphatic regions at 600 MHz in Methanol-d4. 
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Figure 29.IV: MS spectrum of 59. 
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Figure 29.V: 
13
C-NMR spectrum of 59 at 600 MHz in Methanol-d4. 
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Figure 29.VI: HSQC spectrum of 59 at 600 MHz in Methanol-d4. 
For target compounds 58, 60, and 61, only 
1
H-NMR peaks arising from newly introduced 
amide substituents will be discussed in addition to LC-MS confirmation.  
The 
1
H-NMR spectrum of compound 58 is shown in Figure 30.I. A sharp singlet integrating 
for 4H at 3.63 ppm was assigned to H26 and H27. An attached proton test (APT) experiment, 
whose spectrum is shown in Figure 30.II, shows two CH2 groups at 39.4 and 70.7 ppm in the 
aliphatic region and CH2 belongs to protons H27 and H26. H31 was assigned to a sharp 
singlet resonating at 3.43 ppm and integrating to 3H. A pseudomolecular ion m/z [M+H]
+
 = 
434.8, was also observed upon LC-MS analysis. 
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Figure 30.I: 
1
H-NMR spectrum of 58 at 300 MHz in methanol-d4. 
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Figure 30.II:
13-
C-APT spectrum of 58 in methanol-d4. 
For compound 60, whose 
1
H-NMR spectrum is shown in Figure 31, a triplet observed at 0.92 
ppm (J = 7.4 Hz) was assigned to H29 and integrates for 3H. Multiplet signals appearing at 
1.78–1.63 and 1.57–1.42 ppm were assigned to diastereotopic protons H28a and H28b, which 
integrates for 1H in each multiplet. The diastereotopic protons, H27a and H27b were 
assigned to two multiplets appearing at 3.55–3.48 and 3.48–3.41 ppm, respectively, with each 
peak integrating for 1H. A multiplet which appears at 3.93 ppm was assigned to H26 and 
integrates for 1H. A triplet signal at 4.65 ppm (J = 5.8 Hz) was assigned to H30 and 
integrates for 1H. Additionally, a pseudomolecular ion, m/z [M+H]
+
 = 449.0, was observed 
upon LC-MS analysis.    
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Figure 31: 
1
H-NMR spectrum of 60 at 300 MHz in DMSO-d6. 
Figure 32 shows the 
1
H-NMR spectrum of compound 61. The spectrum shows that the 
signals for H30 and H29 protons were resolved into those corresponding to protons above 
and below the ring. H30a indicates a proton above the surface of the ring while H30e indicates 
the one below the ring. In this regard H30a and H29a are equivalent as are H30e and H29e. A 
multiplet signal resonating at 0.66–0.58 ppm was assigned to H30a and H29a while the 
multiplet at 0.77–0.68 ppm was assigned to H30e and H29e both of which integrate for 2H 
each. The H28 proton was assigned to a multiplet at 1.30–1.22 ppm, which integrates for 1H. 
A doublet at 8.53 ppm (J = 4.2 Hz) which integrates for 1H was assigned to H18. A 
pseudomolecular ion mass, m/z [M+H]
+
 = 417.0, for this compound was also observed upon 
LC-MS analysis. Additionally, 20 peaks in the 
13
C-NMR spectrum were observed with some 
carbons co-resonating at the same chemical shifts.    
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Figure 32: 
1
H-NMR spectrum of 61 at 300 MHz in DMSO-d6. 
The compound 74 was prepared from the sulfone-substituted intermediate 73 in a T3P 
mediated acid-amine reaction. The 
1
H-NMR spectrum of 74 is shown in Figure 33. A 
multiplet observed at 8.39 ppm, which integrates for 3H was assigned to H6, H13 and H15. A 
multiplet at 8.03 ppm, which integrates for 3H was assigned to H1, H12 and H16. A triplet 
observed at 8.65 ppm (J = 1.8 Hz) was assigned to H21, and integrates for 1H. A doublet of 
triplets at 8.50 ppm (J = 7.8, 1.9 Hz) was assigned to H17 which integrates for 1H. A singlet 
at 8.46 ppm, which integrates for 1H was assigned to H8. A doublet of triplets observed at 
8.13 ppm (J = 7.8, 1.8 Hz), which integrates for 1H was assigned to H19. A triplet observed 
at 7.90 ppm (J = 7.9 Hz) integrating for 1H was assigned to H18. A sharp singlet at 3.35 ppm 
was assigned to H25 and integrates for 3H. A doublet at 2.84 ppm which integrates for 3H 
was assigned to H29. On LC-MS analysis, 74 showed a pseudomolecular ion at m/z [M+H]
+
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= 406.8 while 19 peaks were observed in the 
13
C-NMR spectrum with some carbon atoms co-
resonating at the same chemical shifts.    
 
Figure 33: 
1
H-NMR spectrum of 74 at 600 MHz in DMSO-d6. 
2.4.1 Chemistry for Series 2 analogues 
The iodinated intermediate 54 was subjected to a regioselective Suzuki-Miyaura coupling 
reaction with (4-(methylsulfinyl)phenyl)boronic acid to afford the sulfoxide-substituted 
intermediate 75 as shown in Scheme 7. A second Suzuki-Miyaura coupling reaction with 3-
carboxyphenylboronic acid gave the benzoic acid common intermediate 76. This intermediate 
was then subjected to an acid catalyzed amide coupling mediated by T3P to give the desired 
target compounds 77-86. The final amide target compounds and yields obtained via this 
synthetic scheme are summarized in Table 3. 
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Scheme 7: Synthetic scheme for the synthesis of amidated imidazopyridazine analogues 77- 86: Reagents and 
conditions  (I) 4-methylsulfinylphenylboronic acid, Pd(PPh3)2Cl2, 1M K2CO3, 1,4-dioxane, 80 °C, 14 h; (II) 3-
carboxyphenylboronic acid, Pd(PPh3)2Cl2, 1M K2CO3, 1,4-dioxane, 100 °C, 15 h ; (III) appropriate amine or 
amine hydrochloride salt, 50 % T3P in EtOAc, DIPEA, 1,4-dioxane, 0–30 °C, 1-3 h. 
Table 3: Series 2 derivatives with respective % yields. 
 
Compound code R1 Yield (%) 
77 
 
4% 
78 
 
43 
79 
 
60 
80 
 
13 
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81 
 
 
4 
82 
 
 
11 
83 
 
 
18 
84 
 
51 
 
85 
 
36 
 
86 
 
50 
 
2.4.2 Characterisation of compound 77 (Step II, Scheme 7) 
A 
1
H-NMR spectrum of 76 is shown in Figure 34. A broad peak at 8.64–8.60 ppm was 
assigned to H16 and integrates for 1H. A sharp singlet at 2.83 ppm, which integrates for 3H 
was assigned to H26. A singlet was also observed at 8.40 ppm, integrating for 1H and was 
assigned to H8. Two 2-proton doublets of an AB spin system are observed at 8.46 (J = 8.81 
Hz) and 7.83 ppm (J = 8.8 Hz) and were assigned to H17, H21 and H18, H20, respectively. A 
triplet integrating for 1H and observed at 7.63 ppm (J = 7.7 Hz) was assigned to H13. A 
relatively deshielded doublet at 8.31 ppm (J = 9.5 Hz) integrating for 1H was assigned to H6. 
A doublet appearing at 7.92 ppm (J = 9.5 Hz) and integrating for 1H was assigned to H1. 
Two doublet of triplets at 8.25 (J = 7.8, 2.0 Hz) and 8.08 ppm (J = 7.7, 1.9 Hz) each 
integrating for 1H were assigned to H12 and H14, respectively.  
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Figure 34: 
1
H-NMR spectrum of 76 at 600 MHz in DMSO-d6. 
2.4.3 Characterisation of the final target compounds (Step III, Scheme 7) 
For the target compounds in this portion of SAR, analogue 77 is used as a representative for 
1
H-NMR interpretation (Figure 35). A triplet at 8.67 (J = 5.5 Hz) integrating for 1H was 
assigned to H30.  H26 was assigned to a peak appearing as a triplet at δ 4.76 ppm (J = 5.6 
Hz). Two quartets at 3.58 (J = 5.9 Hz) and 3.41ppm (5.8 Hz) each integrating for 2H were 
assigned to H28 and H27, respectively.  
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Figure 35: 
1
H-NMR spectrum of 77 at 300 MHz in DMSO-d6. 
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Chapter three 
Pharmacological activity Evaluation of target compounds 
3.1 Overview 
All synthesized molecules were submitted for in vitro antiplasmodium activity testing against 
a chloroquine (CQ)-sensitive strain of P. falciparum (NF54). The potency of each molecule 
was measured as the concentration required to cause 50 % inhibition of the parasite’s growth 
(IC50). A low IC50 value is preferred to minimize undesirable side effects. A transgenic 
parasite line was employed in the luciferase assay, NF54-PfS16-GFP-Luc, for gametocyte 
viability determination. The gametocytocidal assay allows the determination activity of each 
compound at both late and early stage of gametocyte development. Compounds were also 
evaluated for hERG inhibition activity against the hERG potassium channel and was 
determined using in vitro IonWorks patch-clamp electrophysiology.
81,82
 The same 
compounds evaluated for hERG inhibition activity were evaluated for cytotoxicity. 
3.2 Series 1 pharmacological evaluation: in vitro antiplasmodium activity against 
asexual blood stage parasites 
Among the 16 compounds in Table 4, four (64, 67, 68, and 74) were highly potent with IC50 
value less than 100 nM. The compounds with larger cyclic substituent 65 (IC50 = 301 nM), 66 
(IC50 = 136 nM), 69 (IC50 = 105 nM), 70 (IC50 = 521 nM), and 62 (IC50 = 590 nM) were 
found to be relatively less potent. Compounds with a hydroxyl group on the heterocyclic 
amide substituent 67 (IC50 = 18 nM), 68 (IC50 = 66 nM), and 69 (IC50 = 105 nM) were found 
to be more potent than those lacking the hydroxyl group 66 (IC50 = 136 nM), 65 (IC50 = 301 
nM) and 70 (IC50 = 521 nM). The addition of a methyl substituent to the secondary amino 
group of 64 (IC50 = 67 nM) to form 63 (IC50 = 177 nM) was detrimental to activity. Looking 
at compounds 65 (IC50 = 301 nM) and 66 (IC50 = 136 nM), and 70 (IC50 = 521 nM) potent 
activity was observed with the morpholino ring and decreases when this ring is replaced by 
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piperazine and piperidine rings. The sulfone analogue 74 (IC50 = 19 nM) was found to the 
more active than the corresponding sulfoxide 64 (IC50 = 67 nM) revealed that activity was 
improved. Converting the hydroxyl moiety (57 IC50 = 371 nM) to an ether (58 , IC50 = 144 
nM) increased activity. The intermediate carboxylic acid 56 displayed reasonable activity 
with an IC50 value of 114 nM.  
Table 4: Antiplasmodium activity of Series 1 analogues against Plasmodium falciparum 
(NF54). 
 
Compound code R2 R1 NF54 IC50 (nM)
a,b 
MMV652103   7.3 
56 SOMe 
 
114 
57 SOMe 
 
371 
58 SOMe 
 
144 
59 SOMe 
 
141 
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60 SOMe 
 
290 
61 SOMe 
 
209 
62 SOMe 
 
590 
63 SOMe 
 
177 
64 SOMe 
 
67 
65 SOMe 
 
301 
66 SOMe 
 
136 
67 SOMe 
 
18 
68 SOMe 
 
66 
69 SOMe 
 
105 
70 SOMe 
 
521 
74 SO2Me 
  
19 
 
a
IC50, 50 % inhibitory concentration and values are average of ≥ 2 independent experiments.  
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b
Chloroquine (IC50 = 16 nM) and artesunate (IC50 = 7 nM) were used as reference drugs. 
3.4 Series 2 pharmacological evaluation: in vitro antiplasmodium activity 
Among the ten compounds synthesized from Series 2 exploration (Table 5), five showed 
high activity with IC50 < 100 nM (77, 79, 83, 84, and 85). Methylation of 83 (IC50 = 60 nM) 
to form the dimethylated analogue 82 (IC50 = 131 nM) was detrimental to antiplasmodium 
activity. The piperidine moiety in 85 (IC50 = 3 nM) conferred greater activity than the 
morpholine moiety in 84 (IC50 = 16 nM), indicating that –CH2– is preferable to –O– in the 
six-membered ring. Incorporating a more rigid moiety such as cyclopropyl group in 81 (IC50 
= 284 nM) was detrimental to antiplasmodium activity compared to all other flexible moieties 
[(77, 79–85) < 201 nM] with exception of compound 86 (IC50 = 6000 nM). An amide 
functionality with large substituent such as in 86 (IC50 = 6000 nM) was detrimental to 
activity. 
Table 5: Antiplasmodium activity of Series 2 analogues against Plasmodium falciparum 
(NF54). 
 
Compound code R1 NF54 IC50 (nM)
a,b 
MMV652103  7.3 
72 
Luyanda Centani – MSc Thesis, Univeristy of Cape Town, 2018   
77 
 
 
69 
78 
 
198 
79 
 
94 
80 
 
201 
81 
 
284 
82 
 
131 
 
83 
 
60 
 
84 
 
 
9 
85 
 
 
3 
86 
 
6000 
a
IC50, 50 % inhibitory concentration and values are average of ≥ 2 independent experiments.  
b
Chloroquine (IC50 = 16 nM) and artesunate (IC50 = 7 nM) were used as reference drugs. 
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3.5 In vitro P. falciparum gametocytocidal activity 
As already mentioned, gametocytocidal compounds are of interest as they could block 
parasite transmission between man and the mosquito. The gametocytocidal activies of 13 
compounds were evaluated and ranked accordingly (Table 6).    
Table 6: Early and late gametocytocidal activity classification. 
Criteria Classification 
> 70 % inhibition at 5 μM and > 50 % 
inhibition at 1 μM 
High (IC50 < 100 nM) 
> 70 % inhibition at 5 μM and < 50 % 
inhibition at 1 μM 
< 70 % inhibition at 5 μM and > 50 % 
inhibition at 1 μM 
50–70 % inhibition at 5 μM and < 50 % 
inhibition at 1 μM 
Moderate (100 nM < IC50 < 500 nM) 
 
  
<50 % inhibition at 5 μM and < 50 % 
inhibition at 1 μM 
Minimal (IC50 > 500 nM) 
 
Of the 13 compounds tested against early-stage gametocytes, four (74, 79, 84 and 85), 
showed high gametocytocidal activity (Table 7). Moderate gametocytocidal activity was 
observed for compounds 57, 58, 59, 78, 81, and 83. Minimal activity was observed from 
compounds 61, 62, and 60. With regards to late-stage gametocytocidal activity, compounds 
60 and 61 displayed moderate activity. Minimal activity was observed from 62 and all other 
compounds showed high activity.  
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Table 7: In vitro evaluation of selected imidazopyridazines compounds for gametocydal 
activity. 
Compound code 
 
Structure % inhibition in 
early–stage  
gametocytes, 
luciferase 
% inhibition in 
late-stage 
gametocytes, 
luciferase 
1µM 5µM 1µM 5µM 
57 
 
19 62 69 91 
58 
 
  
40 58 53 91 
59 
 
24 17 73 94 
60 
 
 
6 42 45 81 
61 
 
 
 
 
41 49 34 80 
75 
Luyanda Centani – MSc Thesis, Univeristy of Cape Town, 2018   
62 
 
 
 
2 4 26 43 
74 
 
85 96 98 99 
78 
 
39 70 79 96 
79 
 
62 72 80 95 
81 
 
53 67 63 94 
83 
 
55 58 52 92 
84 
 
 
83 79 95 97 
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85 
 
89 86 96 98 
      
 
3.6 Cytotoxicity and hERG channel inhibition activity  
Six selected compounds were evaluated for cytotoxicity using a Chinese Hamster Ovarian 
(CHO) mammalian cell line and hERG channel inhibition activity. The results are shown in 
Table 8. Compounds are considered to have an acceptable hERG inhibition profile if the in 
vitro hERG IC50 exceeds 10 µM and drugs in development are desired to have hERG activity 
in vitro > 30 µM.83 Amidated analogues displayed an encouraging hERG channel inhibition 
activity profile except 65 whose hERG IC50 was below 10 µM. Figure 36 depicts a plot of 
tPSA against hERG activity IC50 showing a positive moderate correlation. All compounds 
were found to have low cytotoxic and the positive values of log(SI) suggest that compounds 
are more selective towards the PfNF54 strain than the CHO cells.   
Table 8. Cytotoxicity and hERG activity results. 
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Compound 
code 
R1 CHO 
C50 (µM)
 
hERG 
IC50 (µM) 
NF54 IC50 
(µM)a,b 
SI = CHO 
C50 / NF54 
IC50  
Log(SI) 
MMV652103  > 234 0.9 0.0073 > 30000 4.48 
63 
 
165 20.3 0.177 932 2.96 
64 
 
 75.5 17.9 0.067 1127 3.05 
65 
 
83 9.0 0.301 275 2.44 
66 
 
185 23.4 0.136 1360 3.13 
67 
 
> 231 20.9 0.018 12833 4.11 
68 
 
ND 30.4 0.066 ND ND 
69 
 
> 217 36.0 0.105 2067 3.32 
hERG, human ether-a go-go-related gene; ND, no data; SI, selectivity index, 
a
IC50, 50 % 
inhibitory concentration and values are average of ≥ 2 independent experiments; 
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Figure 36: Scatter plot of hERG activity and total polar surface area. 
3.7 Conclusions 
A total of 26 imidazopyridazines were synthesized and evaluated for their in vitro 
antiplasmodium activities. A selection of the compounds showed superior activity compared 
with the lead compound MMV652103 while a number were less potent. Results from testing 
against sexual gametocyte stage of the parasite suggest that late-stage gametocytes were more 
sensitive, as many molecules that were moderately or minimally active against early stage 
gametocytes displayed higher activity against late-stage gametocytes. Amidated analogues 
generally displayed a promising cytotoxicity and hERG channel inhibition profile.  
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Chapter four 
Physicochemical property evaluation and structure-property relationships 
4.1 Overview  
The melting points of the compounds were determined experimentally using a Stuart SMP40 
melting point apparatus. The commercially available reagent 3-amino-5-methylisozole was 
used for instrument calibration and the temperature was set to increase at 5 °C per minute. 
The mean average melting point of each compound using the instrument, and 1 °C was added 
and subtracted from this to obtain the melting point interval. The solubility of all synthesized 
compounds was evaluated via turbidimetric and HPLC-based kinetic solubility assays. 
Solubility assays are discribed fully in experimental section in chapter six. 
Solubility results were used to rank the compounds following the classification listed in 
Table 9 and Table 10.
43,84
  
Table 9: Turbidimetric kinetic solubility rankings. 
 
 
 
 
Table 10: HPLC-based kinetic solubility rankings. 
Classification HPLC-based solubility (µM) 
High soluble ≥ 150  
Classification Turbidimetric solubility (µM) 
highly insoluble < 1 
Moderately soluble  1-100 
Highly soluble > 100 
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Moderately soluble 50-150  
Low 11-50  
Very low < 11 
 
In an attempt to identify which physicochemical factor contributed to aqueous solubility, the 
physicochemical parameters were plotted [log(solubility) against melting point, cLogP, and 
tPSA]. Table 11 uses Evan’s guidelines to determine the degree of correlation strength based 
on R
2
 values.
85
 
Table 11: Correlation strength. 
R
2
 Classification 
0.0–0.19 Very weak 
0.20–0.39 Weak 
0.40–0.59 Moderate 
0.60–0.79 Strong 
0.80–1.00 Very strong 
 
4.2 Structure property relationship of Series 1  
4.2.1 Effect of incorporating hydrogen bonding donors and acceptors to improve 
solubility 
The solubility and melting point values of the compounds obtained from Series 1 are listed in 
Table 12. Turbidimetric kinetic solubility results: Compounds 58 (200 µM) and 61 (200 µM) 
were highly soluble, and compound 60 (80 µM) was moderately soluble. Introducing a bulky 
81 
Luyanda Centani – MSc Thesis, Univeristy of Cape Town, 2018   
cyclic group in 62 (< 5 µM) was detrimental to solubility. Compounds such as 58 (200 µM) 
with linear alkyl amide substituents and hydrogen bond acceptor moieties conferred greater 
solubility (200 µM).  
HPLC–based solubility results: Compound 58 (155 µM) was highly soluble, while 
compounds 60 (10 µM) and 61 (10 µM) were very lowly soluble. On the other hand, 
compound 74 (< 5 µM) was poorly soluble compared to the highly soluble sulfoxide version 
64, indicating that the inclusion of a sulfone moiety lowered the aqueous solubility. High 
molecular weight is generally detrimental to solubility, as molecular weight increases so does 
cLogP. The effect of increasing solubility through incorporation of hydrogen bonding donor 
and acceptor groups is outweighed by high molecular weight [decreasing solubility: 64 (200 
µM) > 69 (170 µM) > 62 (< 5 µM)] [increasing molecular weight: 62 (390.5 g/mol) < 69 
(460.6 g/mol) < 62 (488.6 g/mol)].  
Table 12: Solubility and melting points results of Series 1. 
 
 
Compound 
code 
R2  R1 Solubility (µM)
  
Melting point 
(°C) 
clogP
 
tPSA
 
MMV652103   (<5
*
) 134.0–136.0 2.50 98.47 
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56 SOMe 
 
ND ND 2.91 84.56 
57 
 
SOMe 
  
ND 
 
207.0–209.0 
 
1.98 96.59 
58 SOMe 
 
200 (155
*
) 315.7–317.5 2.61 85.59 
59 SOMe 
 
ND 192.6–194.6 2.80 76.36 
60 SOMe 
 
80 (10
*
) 268.9–270.9 2.63 96.59 
61 SOMe 
 
200 (10
*
) 236.4–238.4 2.94 76.36 
62 SOMe 
 
SM 264.0–266.0 3.91 85.49 
63 SOMe 
 
200* ND 2.64 67.57 
64 SOMe 
 
195* 241.0–243.0 2.63 76.36 
65 SOMe 
 
70* 268.0–270.0 3.83 67.60 
66 SOMe 
 
75* 247.8–249.8 2.73 76.80 
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ND = not determined; cLogP, calculated log P, determined using StarDrop version 6.4; tPSA, 
total polar surface area, determined using StarDrop version 6.4; SM, solid material not 
dissolved after vortexing ( < 5 µM);* HPLC-based solubility. 
4.2.2 Effect of reducing cLog P to improve solubility 
Correlation with cLogP (HPLC-based method): As shown in Figure 37, cLogP is very 
weakly and negatively correlated (R
2
 = 0.1275), therefore, the observed changes on solubility 
was not attributed to cLogP changes. 
67 SOMe 
 
200* ND 2.07 87.80 
68 SOMe 
 
200* ND 2.43 87.80 
69 SOMe 
 
170* 243.2–245.2 2.59 87.80 
70 SOMe 
 
200* 248.0–250.0 2.48 79.60 
74 SO2Me 
 
(<5*) 250.5–252.5 2.25 93.43 
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Figure 37: Series 1 log[Solubility (mg/mL)] versus cLogP. 
All compounds had higher melting point relative to the parent compound MMV652103. The 
high melting points observed suggests that the compounds had higher crystal lattice energy 
than the parent compound.
86
 However, compounds with low melting points are preferred as 
they are less likely to have many polymorphs.
87
 As shown in Figure 38, melting point was 
very weakly correlated to log (solubility) (R
2
 = 0.1827), therefore, melting point was not a 
causation for the observed changes on solubility.  
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Figure 38:  Series 1 log[Solubility (mg/mL)] versus melting point. 
tPSA is important for permeation through cells, and is influenced by polar atoms such as 
oxygen and nitrogen, which also influence solubility. As shown in Figure 39, a plot of 
log(solubility) versus tPSA shows a very weak correlation (R
2
 = 0.124), therefore, tPSA was 
not the causation for the changes observed on solubility. 
 
Figure 39: Series 1 log[Solubility (mg/mL)] versus tPSA. 
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4.3 Structure property relationship of Series 2 
4.3.1 Effect of incorporating hydrogen bonding donors and acceptors to improve 
solubility 
Turbidimetric solubility results: All Series 2 compounds were found to be highly soluble over 
the entire concentration range (0–200 µM) except compound 86 (< 5 µM). Introducing a 
bulky cyclic group in 86 (< 5 µM) was detrimental to solubility. The solubility and melting 
points of the compounds obtained from Series 2 are listed in Table 13. 
Table 13: Solubility and melting points of Series 2 compounds. 
 
Compound 
code 
 R1 Solubility 
(µM)  
Melting 
point (°C) 
cLogP
 
tPSA
 
MMV652103  (<5
*
) 134.0–136.0 2.50 98.47 
77 
 
ND ND 1.98 96.59 
78 
 
200  206.3-208.3 2.61 85.59 
79 
 
200 228.7-230.7 2.80 76.36 
80 
 
ND ND 2.63 96.59 
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ND = not determined; cLogP, calculated log P, determined using StarDrop version 6.4; tPSA, 
total polar surface area, determined using StarDrop version 6.4; SM, solid material not 
dissolved after vortexing ( < 5 µM);* HPLC-based solubility. 
4.3.2 Effects of changing physicochemical properties to improve solubility (Series 2) 
 Turbidimetric solubility: The changes in cLogP are shown in Figure 40. An excessively 
high cLogP value impacted the aqueous solubility, as observed in compound 86 (cLogP 3.91, 
<5 µM). Furthermore, Figure 41 shows that cLogP is weakly correlated to solubility (R2 = 
0.3731), therefore, the observed changes on solubility was not be attributed to cLogP 
changes.   
  
81 
 
200  250.5–252.5 2.94 
  
76.36 
82 
 
ND ND 2.34 76.36 
83 
 
200 256.1–258.1 2.64 67.57 
84 
 
200 ND 3.83 67.57 
85 
 
200 256.4–258.4 2.73 76.80 
86 
 
SM 
 
308.4–310.4 3.91 85.59 
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Figure 40: Solubility versus cLogP of Series 2 compounds. 
 
Figure 41: Series 2 log[Solubility (mg/mL)] versus cLogP. 
The melting point and solubility are higher than the parent compound. As shown in Figure 
42, melting point is strongly and negatively correlated, therefore, melting point was not 
causation for the observed changes on solubility. 
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Figure 42: Series 2 log[Solubility (mg/mL)] versus melting point. 
As shown in Figure 43, a plot of log(solubility) versus tPSA shows weakly correlated (R
2
 = 
0.2837), therefore, tPSA was not the causation for the changes observed on solubility. 
 
Figure 43: Series 2 log[Solubility (mg/mL)] versus tPSA. 
4.5 Conclusions  
Series 1 and Series 2 compounds were synthesized and their solubility was analysed using 
kinetic turbidimetric and HPLC-based methods. Physicochemical parameters affecting 
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solubility such as cLogP, tPSA and melting point were analysed to deduce which 
physicochemical factor affected solubility. The parent compound displayed poor solubility, 
which was improved by designing derivatives that incorporated hydrogen bonding donors 
and acceptors. The cLogP of both Series 1 and Series 2 compounds was negatively 
correlated, which implies that the observed improvements in aqueous solubility was not 
simply caused by increasing or decreasing cLogP. In Series 1 compounds melting point was 
negatively correlated with solubility but strongly negatively correlated in Series 2 
compounds. 
 In Series 2 compounds, molecules returned highly soluble over the entire concentration 
range of 0–200 µM. In both series, tPSA was negatively correlated; hence it was not a key 
factor contributing to the observed improvement in solubility. In the Series 1 and Series 2, 
log(Solubility) was negatively correlated with melting point, cLogP, and tPSA. Therefore, 
incorporated hydrogen bonding donors and acceptors moieties were responsible for the 
improved aqueous solubility. 
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Chapter Five 
Summary and conclusions 
A series of amidated imidazopyridazine derivatives designed to improve solubility and 
address hERG potassium channel inhibition activity was synthesized and evaluated for in 
vitro antiplasmodium activity against asexual blood and sexual gametocyte stage parasites. 
All compounds were characterised by 
1
H-NMR (1D and 2D), 
13
C-NMR, LC-MS and melting 
point.  
The solubility of the compounds was determined using kinetic solubility turbidimetric- and 
HPLC-based methods.  
The following conclusions can be drawn from the in vitro antiplasmodium (asexual blood and 
sexual gametocyte stage parasites), hERG, cytotoxicity, and as solubility: 
 In comparison to the lead compound MMV652103, structural modifications generally 
led to compounds with reduced potency albeit analogues showing potency in the low 
nanomolar range were identified. 
 Switching moieties from the right-hand side to left-hand side did not necessarily 
preserve antiplasmodium activity.    
 Compounds that displayed high antiplasmodium activity (IC50 < 100 nM) against 
asexual blood stage also displayed highest inhibition (> 70 %, 1 and 5 µM) against the 
sexual early and late-stage gametocytes. 
 Relative to the parent compound, strategies to improve solubility generally resulted in 
solubility enhancement in the new amidated analogues.  
 Several compounds were identified with encouraging cytotoxicity and hERG profiles. 
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5.1 Future work 
Based on findings from Series 1 and Series 2 studies described in this dissertation, chemical 
features identified to be important for potency and solubility can be used to design the next 
generation of analogues proposed in Figure 44. Since the amide functionality is tolerated for 
both solubility and antiplasmodium activity, to further expand SAR, amide functionalities can 
be introduced on the right-hand and left-hand side portions of the molecule at the para and 
meta position. Furthermore, based on previous work done that delivered compounds active in 
vivo, SAR studies can be expanded to include a scaffold change from the imidazopyridazine 
scaffold to the pyrazolopyridine
68
 scaffold as depicted in Figure 44. 
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Figure 44: Future work molecules. 
 
 
 
 
 
94 
Luyanda Centani – MSc Thesis, Univeristy of Cape Town, 2018   
Chapter six 
Experimental 
6.1 Chemicals, solvents, and apparatus  
Reagents and chemicals used during the experiments were purchased from Sigma-Aldrich 
and Combi-Blocks used without further purification. All solvents that were used during the 
experiments were anhydrous except ethanol which was analytical reagent (AR) grade and 
absolute (99.9 %). The progress of each reaction was monitored by a combination of thin 
layer chromatography (TLC) and liquid chromatography-mass spectrometry (LC-MS). The 
TLC plates employed were sourced from Merck (TLC Silica gel 60 F254 coated on aluminium 
sheets). All TLC plates were developed in a sealed container and the retardation factor (Rf) 
was used to determine a suitable mobile phase for purification in column chromatography. 
The TLC plates were visualized under ultraviolet light (UV 254 and 366 nm). An Agilent 
LC-MS instrument with the following components was used to monitor the progress of 
reactions including percent purity determinations: Agilent 1260® Infinity Binary Pump, 
Agilent 1260® Infinity Diode Array Detector, Agilent 1290® Infinity Column Compartment, 
Agilent 1260® Infinity Autosampler, Agilent 6120® Quadrupole LC/MS, and Peak 
Scientific® Genius 1050 Nitrogen Generator. An X-bridge® (C18, 2.5μm, 3.0 mm (ID) x 50 
mm length) column maintained at 35 °C was used. The chromatographic mobile phase was 
composed of 10 mM aqueous ammonium acetate (NH4Ac) spiked with 0.4 % acetic acid 
while the organic phase was composed of 10 mM NH4Ac in methanol spiked with 0.4 % 
acetic acid. The mass spectra were acquired using electrospray ionisation (ESI) or 
atmospheric pressure chemical ionization (APCI) in the positive ionisation mode unless 
otherwise stated. The manual glass tube columns employed Fluka high purity grade silica gel 
(pore size 60 Å, 70–230 mesh, 63–200 μm). Additionally, Analtech Uniplate preparative 
TLC (prep-TLC) plates (20 × 20 cm, 2000 microns) were used for prep-TLC purifications. 
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The solvents used as mobile phases were AR grade and were used without further distillation. 
1
H-NMR and 
13
C-NMR spectra were acquired on either Bruker AV 400 (
1
H 400.0, 
13
C 100.6 
MHz) or Varian Mercury 300 (
1
H 300.1, 
13
C 75.5 MHz) spectrometers housed in the 
Department of Chemistry at the University of Cape Town. All 
1
H-NMR and 
13
C-NMR 
spectra were acquired at 30 °C in deuterated solvents (DMSO-d6 or CD3OD). The one-
dimensional 
1
H-NMR and 
13
C-NMR spectra were processed using MestReNova v10.0.2-
15465. Multiplicity patterns are reported using the following abbreviations s = singlet, d = 
doublet, t = triplet, m = multiplet, dd = doublet of doublets, br = broad, br s = broad single, br 
m = broad multiplet, t = triplet, dt = doublet of triplets, td = triplets of doublets, q = quartet, 
qd = quadruplet of doublets, ddt = doublet of doublets of triplets. Coupling constants (J 
values) are reported in Hertz (Hz). Where assignment of 
1
H-NMR and 
13
C-NMR signals was 
ambiguous, two-dimensional NMR spectra from Correlation Spectroscopy (COSY), and 
Heteronuclear Single Quantum Coherence (HSQC) spectroscopy were acquired to facilitate 
accurate assignments. The Attached Proton Test (APT) was employed to identify negative 
and positive carbon. All final compounds were subjected to purity check experiments using 
LC-MS to ensure an acceptable level of purity (≥ 95 %).  
6.2 Synthesis  
6.2.1 Synthesis of 53. 
A solution of 3-amino-6-chloropyridazine (1.0 equiv), deionized water (7.7 mmol/ 10 mL), 
ethanol (7.7 mmol/15 mL) and bromoacetaldeyde diethylacetal (2.0 equiv) and 48 % aqueous 
HBr (1.0 equiv) were added. The reaction mixture was refluxed at 103 °C over 16 h. After all 
starting material was consumed; the solvents were removed in vacuo. The crude material was 
dissolved in dichloromethane and washed with saturated solution of NaHCO3, NaCl and 
dried over Na2SO4 anhydrous. 
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6-Chloroimidazo [1, 2-b]pyridazine 53.
67
 
 
 Beige solid (5.63 g, 79 %); m.p 117.9–119.9 °C; Rf = 0.23 (3 % MeOH/DCM); 1H NMR 
(300 MHz, Methanol-d4) δ 8.12–8.10 (br, 1H, H7), 8.02 (d, J = 9.5 Hz, 1H, H6), 7.78 (d, J = 
1.3 Hz, 1H, H8), 7.28 (d, J = 9.5 Hz, 1H, H1); 
13C NMR (101 MHz, DMSO) δ 146.88, 
137.63, 134.81, 128.00, 119.51, 117.94. LC-MS, ESI/APCI: m/z [M + H]
+
 = 154.1, tr = 0.339 
min. Purity = 98 %. 
6.2.2 General procedure for synthesis of 54 and 72.  
The intermediate 53 (1.0 equiv) was dissolved in DMF (30 mmol / 30 mL), and the mixture 
was stirred and flushed with nitrogen for 30 mins. NIS (1.1 equiv) was added in one portion, 
stirred at 30 °C for 6 days. The DMF was removed in vacuo. The residue was dissolved in 80 
mL DCM and was washed with saturated solution of NaSO2O7. The compound was dried 
over MgSO4 and filtered and washed with DCM, DCM was removed in vacuo. The described 
method was also used to synthesize 72 and its starting material is compound 71. 
6-Chloro-3-iodoimidazo[1,2-b]pyridazine 54.
67
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  Yellow solid (8.56 g, 79 %); m.p 117.9–119.9 °C; Rf = 0.54 (2 %MeOH/DCM). 1H NMR 
(300 MHz, Methanol-d4) δ 8.02 (d, J = 9.5 Hz, 1H, H6), 7.87 (s, 1H, H8), 7.34 (d, J = 9.5 Hz, 
1H, H1); 
13
C NMR (101 MHz, CDCl3) δ 148.52, 139.47, 126.23 (2C), 120.45, 77.42. LC-
MS, ESI/APCI: m/z [M + H]
+
 = 279.7, tr = 2.52 min. Purity = 78 %. 
3-Iodo-6-(3-(methylsulfonyl)phenyl)imidazo[1,2-b]pyridazine 72. 
 
Yellow solid (0.855 g, 87 %). m.p 204.3–206.3 °C; Rf = 0.68 (4 % MeOH/DCM). 1H NMR 
(400 MHz, DMSO-d6) δ 8.65 (t, J = 1.9 Hz, 1H, H15), 8.48 (dt, J = 7.9, 1.83 Hz, 1H, H11), 
8.29 (d, J = 9.5 Hz, 1H, H6), 8.13 (dt, J = 7.8, 1.9 Hz, 1H, H13), 8.03–7.97 (m, 2H, H1 & 
H8), 7.90 (t, J = 7.9 Hz, 1H, H12), 3.34 (s, 3H, H18); 
13C NMR (101 MHz, DMSO) δ 150.78, 
142.41, 141.03, 140.76, 136.51, 132.34, 130.89, 128.96, 126.60, 125.75, 117.07, 72.70, 
43.97. LC-MS, ESI/APCI: m/z [M + H]
+
 = 399.6, tr = 2.45 min. Purity = 100 %.  
6.2.3 General procedure for Suzuki-Miyaura coupling at 80 °C and 100 °C of 
compounds 53, 54, 55 and 72. 
The compound 54 (1.0 equiv), 4-boronobenzoic acid (1.1 equiv), Pd(PPh3)2Cl2 (0.05 equiv) 
were dissolved in DMF (1.79 mmol / 5 mL). The resulting mixture was flushed in nitrogen 
for 30 mins, after which 1 M solution of K2CO3 (1.05 equiv) was added to the reaction 
mixture. The reaction mixture was heated to 80 °C and stirred for 12 h. DMF in the reaction 
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mixture was removed using toluene in vacuo. The intermediate was purified using flash 
column chromatography 1 % methanol / ethyl acetate and acidified with drops of glacial 
acetic acid. The same procedure was repeated at 100 °C for the following compounds as 
starting materials 55, 72. 
4-(6-Chloroimidazo [1,2-b]pyridazin-3-yl)benzoic acid 55. 
 
Yellow solid (4.42 g, 85 %); m.p not determined; Rf = 0.38 (4 % MeOH/ ethyl acetate); 
1
H 
NMR (600 MHz, DMSO-d6) δ 8.43 (s, 1H, H8), 8.32 (d, J = 9.4 Hz, 1H, H6), 8.23 (d, J = 8.8 
Hz, 2H, H12 & H14), 8.08 (d, J = 8.8 Hz, 2H, H11 & H15), 7.46 (d, J = 9.5 Hz, 1H, H1); 
13
C 
NMR (151 MHz, DMSO) δ 167.80, 147.02, 139.66, 135.22, 131.94, 131.28, 130.19 (2C), 
128.71, 127.44, 126.33 (2C), 119.66.  LC-MS, ESI/APCI: m/z [M + H]
+
 = 273.87, tr = 2.54 
min. Purity = 93 %. 
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4-(6-(3-(Methylsulfinyl)phenyl)imidazo[1,2-b]pyridazin-3-yl)benzoic acid 56. 
 
Yellow solid (1.38 g, 59 %); m.p not determined; Rf = 0.36 (10 % MeOH / DCM). 
1
H NMR 
(600 MHz, DMSO-d6) δ 8.43 (t, J = 1.8 Hz, 1H, H16), 8.36–8.29 (m, 3H, H12 & H8 & H6), 
8.18 (d, J = 8.4 Hz, 2H, H18 & H20), 8.05 (d, J = 8.3 Hz, 2H, H17 & H21 ), 7.96 (d, J = 9.5 
Hz, 1H, H1), 7.87 (dt, J = 6.9, 1.2 Hz, 1H, H14), 7.81 (t, J = 7.7 Hz, 1H, H13), 2.86 (s, 3H, 
H27); 
13C NMR (151 MHz, DMSO) δ 169.65, 150.57, 148.14, 140.66, 139.63, 136.74, 
134.20, 130.63, 129.86 (2C), 129.55 (2C), 128.79, 128.43, 126.95, 125.60 (2C), 122.52, 
116.17, 43.73. LC-MS, ESI/APCI: m/z [M + H]
+
 = 377.8, tr = 2.52 min. Purity = 95 %. 
4-(6-(3-(Methylsulfonyl)phenyl)imidazo[1,2-b]pyridazin-3-yl)benzoic acid 73. 
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 Yellow solid (0.798 g, 41 %);  Rf = 0.38 (4 % MeOH/DCM); 
1
H NMR (400 MHz, DMSO-
d6) δ 8.67 (t, J = 1.8 Hz, 1H, H15), 8.52 (dt, J = 7.9, 1.9 Hz, 1H, H11), 8.43 (s, 1H, H8), 8.40 
(d, J = 9.5 Hz, 1H, H6), 8.34 (d, J = 8.7 Hz, 2H, H22 & H24), 8.12 (dt, J = 7.8, 1.9 Hz, 1H, 
H13), 8.09 (d, J = 8.3 Hz, 2H, H21 & H25), 8.05 (d, J = 9.6 Hz, 1H, H1), 7.91 (t, J = 7.9 Hz, 
1H, H12), 3.35 (s, 3H, H19); 
13C NMR (101 MHz, DMSO) δ 168.44, 150.23, 142.44, 140.08, 
136.79, 135.04, 131.26, 132.36, 131.21, 130.96, 130.06 (2C), 128.82, 127.78, 127.17, 126.09 
(2C), 125.87, 116.57, 43.96.  LC-MS, ESI/APCI: m/z [M + H]
+
 = 393.8, tr = 3.56 min. Purity 
= 97 %.  
6-(3-(Methylsulfonyl)phenyl)imidazo[1,2-b]pyridazine 71. 
 
Yellow solid (0.650 g, 63 %); m.p 201.9–203.9 °C; Rf = 0.54 (4 % MeOH/DCM);  1H NMR 
(400 MHz, DMSO-d6) δ 8.54 (t, J = 1.9 Hz, 1H, H15), 8.41–8.35 (m, 2H, H8 & H 11), 8.23 
(d, J = 9.5 Hz, 1H, H6), 8.07 (dt, J = 12.9, 1.2 Hz, 1H, H13), 7.88 (d, J = 9.8 Hz, 1H, H1), 
7.85–7.81 (m, 2H, H12 & H7), 3.29 (s, 3H, H18); 13C NMR (101 MHz, DMSO) δ 150.30, 
142.14, 138.29, 136.60, 134.87, 132.39, 130.91, 128.73, 126.55, 125.53, 117.86, 116.81, 
43.94. LC-MS, ESI/APCI: m/z [M + H]
+
 = 273.9, tr = 2.69 min. Purity = 98 %. 
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6.2.4 General procedure for amide coupling via propylphosphonic anhydride solution ≥ 
50 wt. % in ethyl acetate to form 57-69. 
An ice water cooled mixture containing a dissolved carboxylic acid intermediate 56 (1.0 
equiv), DIPEA (7.0 equiv), appropriate amine (3.0 equiv) in DMF was stirred and 
propylphosphonic anhydride solution ≥ 50 wt. % in ethyl acetate (4.0 equiv) solution was 
added dropwise to afford a desired compounds.      
N-Allyl-4-(6-(3-(methylsulfinyl)phenyl)imidazo[1,2-b]pyridazin-3-yl)benzamide 59. 
 
Yellow solid (0.0232 g, 14 %); m.p 192.6–194.6 °C;  Rf = 0.32 (2 % MeOH/DCM); 1H NMR 
(600 MHz, Methanol-d4) δ 8.41 (t, J = 1.8 Hz, 1H, H15), 8.26 (d, J  = 8.6 Hz, 2H, H19 & 
H21), 8.23 (dt, J = 5.2, 1.26 Hz, 1H, H11), 8.18 (s, 1H, H8), 8.13 (d, J = 9.5 Hz, 1H, H6), 
7.98 (d, J = 8.5 Hz, 2H, H18 & H22), 7.86–7.81 (m, 2H, H1 & H13), 7.75 (t, J = 7.9 Hz, 1H, 
H12), 6.00 (ddt, J = 17.1, 10.3, 5.5 Hz, 1H, H33), 5.30 (dq, J = 17.2, 1.7 Hz, 1H, H31), 5.18 
(dq, J = 10.3, 1.5 Hz, 1H, H32), 4.06 (dt, J = 5.6, 1.7 Hz, 2H, H28), 2.89 (s, 3H, H27); 
13
C 
NMR (151 MHz, MeOD) δ 167.97, 150.86, 146.36, 139.85, 136.81, 134.26, 133.54, 133.10, 
131.25, 130.02, 129.53, 127.94, 127.34 (2C), 126.17 (2C), 125.64, 125.11, 121.99, 116.34, 
114.98, 42.34, 41.98. LC-MS, ESI/APCI: m/z [M + H]
+
 = 416.8, tr = 2.66 min. Purity = 97 %.  
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N-(2-Methoxyethyl)-4-(6-(3-(methylsulfinyl)phenyl)imidazo[1,2-b]pyridazin-3-
yl)benzamide 58. 
 
Yellow solid (0.158 g, 69 %); m.p 315.7–317.5 °C; Rf = 0.40 (2 % MeOH/DCM);  1H NMR 
(300 MHz, Methanol-d4) δ 8.45 (t, J = 1.8 Hz, 1H, H16), 8.35–8.25 (m, 3H, (H18, H20 & 
H12)), 8.24 (s, 1H, H8), 8.18 (d, J = 9.6 Hz, 1H, H6), 7.99 (d, J = 8.3 Hz, 2H, H17 & H21), 
7.94–7.81 (m, 2H, H14 & H1), 7.79 (t, J = 7.7 Hz, 1H, H13 ), 3.63 (s, 4H, H26 & H27), 3.43 
(s, 3H, H31), 2.91 (s, 3H, H30); 
13C NMR (101 MHz, MeOD) δ 168.19, 157.97, 150.70, 
146.16, 141.42, 136.61, 133.33, 133.06, 131.16, 130.04, 129.48, 127.33 (2C), 125.99 (2C), 
125.57, 125.12, 121.91, 116.32, 70.66, 57.60, 42.30, 39.42. LC-MS, ESI/APCI: m/z [M + H]
+
 
= 434.8, tr = 3.01 min. Purity = 98 %. 
N-Cyclopropyl-4-(6-(3-(methylsulfinyl)phenyl)imidazo[1,2-b]pyridazin-3-yl)benzamide 61. 
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Yellow solid (0.071 g, 43 %); m.p. 236.4–238.4 °C;  Rf = 0.59 (10 % MeOH/DCM); 1H 
NMR (300 MHz, DMSO-d6) δ 8.53 (d, J = 4.2 Hz, 1H, H18), 8.46-8.43 (br , 1H, H24), 8.43–
8.34 (m, 4H, (H8, H13, H15, & H20)), 8.31 (d, J = 7.5 Hz, 1H, H6), 8.05–7.96 (m, 3H, (H12, 
H16 & H22)), 7.89 (d, J = 7.7 Hz, 1H, H1), 7.82 (t, J = 7.7 Hz, 1H, H21), 2.87 (s, 3H, H27), 
1.30–1.22 (m, 1H, H28), 0.77–0.68 (m, 2H, H30e & H29e), 0.66–0.58 (m, 2H, H30a & H29a); 
13C NMR (101 MHz, DMSO) δ 167.39, 150.93, 148.26, 140.14, 136.69, 135.04, 133.74, 
131.35, 130.63, 129.62, 128.12, 127.42, 127.09 (2C), 126.12 (2C), 125.72, 122.67, 116.80, 
43.77, 28.52, 23.58, 6.22. HPLC-MS, ESI/APCI: m/z [M + H]
+
 = 417.0, tr = 0.858 min. 
Purity = 97 %.  
N-(1-Hydroxybutan-2-yl)-4-(6-(3-(methylsulfinyl)phenyl)imidazo[1,2-b]pyridazin-3-
yl)benzamide 60. 
 
Yellow solid (0.0273 g, 38 %); m.p. 268.9–270.9 °C; Rf = 0.36 (8 % MeOH/DCM);  1H 
NMR (400 MHz, DMSO-d6) δ 8.44 (s ,1H, H8), 8.42 (t, J = 1.8 Hz, 1H, H16), 8.40–8.35 (m, 
3H, (H6, H18 & H20)), 8.32 (dt, J = 7.7, 1.7 Hz, 1H, H12), 8.06 (d, J = 8.9 Hz, 2H,  H17 & 
H21)), 8.01 (d, J = 9.5 Hz,1H,  H1), 7.89 (dt, J = 8.1, 1.7 Hz, 1H, H14), 7.83 (t, J = 7.4 Hz, 
1H, H13), 4.65 (t, J = 5.8 Hz, 1H, H30), 3.97–3.85 (m, 1H, H26), 3.55–3.48 (m, 1H, H27a), 
3.48–3.41 (m, 1H, H27b), 2.87 (s, 3H, H32), 1.78–1.63 (m, 1H, H28a), 1.57–1.42 (m, 1H, 
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H28b), 0.92 (t, J = 7.4 Hz, 3H, H29); 
13C NMR (101 MHz, DMSO) δ 166.22, 150.96, 148.27, 
140.14, 136.71, 135.03, 134.24, 131.26, 130.66, 129.62, 128.27, 127.48, 127.12 (2C), 126.12 
(2C), 125.73, 122.70, 116.80, 63.60, 53.63, 43.76, 24.16, 11.15; HPLC-MS, ESI/APCI: m/z 
[M + H]
+
 = 449.0, tr = 0.834 min; Purity = 100 %. 
N-(2-Hydroxyethyl)-4-(6-(3-(methylsulfinyl)phenyl)imidazo[1,2-b]pyridazin-3-
yl)benzamide 57. 
 
Yellow solid (0.0711 g, 10 %); m.p. 207.0–209.0 °C; Rf = 0.48 (10 % MeOH/DCM); 1H 
NMR (300 MHz, Methanol-d4) δ 8.64–8.58 (br, 1H, H12), 8.58–8.51 (m, 2H, H6 & H8), 8.44 
(d, J = 9.6 Hz, 1H, H1), 8.37 (dt, J = 7.8, 1.40 Hz, 1H, H16), 8.31 (d, J = 8.5 Hz, 2H, H20 & 
H18), 8.10 (d, J = 8.6 Hz, 2H, H17 & H21), 7.94 (dt, J = 7.9, 1.5 Hz, 1H, H14), 7.86 (t, J = 
7.8 Hz, 1H, H15), 3.78 (t, J = 5.8 Hz, 2H, H26), 3.58 (t, J = 5.8 Hz, 2H, H25), 2.92 (s, 3H, 
H30); 
13C NMR (151 MHz, DMSO) δ 166.26, 151.58, 148.21, 139.41, 136.33, 134.18, 
132.77, 130.77, 130.72, 129.74, 128.18, 127.71 (2C), 126.51 (2C), 125.99 (2C), 122.73, 
118.20, 60.23, 43.70, 42.70;  LC-MS, ESI/APCI: m/z [M + H]
+
 = 421.1, tr = 2.08 min. Purity 
= 95 %. 
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N-(4-Methoxycyclohexyl)-4-(6-(3-(methylsulfinyl)phenyl)imidazo[1,2-b]pyridazin-3-
yl)benzamide 62. 
 
Yellow solid (0.0523 g, 40 %); m.p 264.0–266.0 °C; Rf = 0.66 (10 % MeOH/DCM); 1H 
NMR (600 MHz, DMSO-d6) δ 8.43 (s, 1H, H8), 8.40 (t, J = 1.9 Hz, 1H, H16), 8.38–8.34 (m, 
3H, (H18, H20, H24)), 8.32–8.27 (m, 2H, H12 & H6), 8.02–7.97 (m, 3H, (H17, H21, & H1)), 
7.88 (dt, J = 7.8, 1.7 Hz, 1H, H14), 7.81 (t, J = 7.7 Hz, 1H, H13), 3.83–3.74 (m, 1H, H25), 
3.24 (s, 1H, H31), 3.15–3.08 (m,1H, H30), 2.85 (s, 3H, H34), 2.07–2.00 (m, 2H, H28e & 
H29e), 1.92–1.85 (m, 2H, H27e & H26e), 1.40 (qd, J = 12.9, 3.7 Hz, 2H, H26a & H27a), 
1.21 (qd, J = 4.2, 3.4, 2.8 Hz, 2H, H28a & H29a); 
13
C NMR (151 MHz, DMSO) δ 165.52, 
150.92, 148.19, 140.13, 136.65, 135.03, 134.03, 131.27, 130.66, 129.62, 128.25, 127.40, 
127.11 (2C), 126.08 (2C), 125.72, 122.67, 116.81, 78.307, 55.542, 48.439, 43.716, 42.87, 
40.55, 30.77, 30.42. LC-MS, ESI/APCI: m/z [M + H]
+
 = 489.1, tr = 2.83 min. Purity = 96 %.  
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N-Methyl-4-(6-(3-(methylsulfinyl)phenyl)imidazo[1,2-b]pyridazin-3-yl)benzamide 64. 
 
Yellow solid (0.0329 g, 28 %); m.p. 241.3–243.3 °C; Rf = 0.23 (4 % MeOH/DCM); 1H NMR 
(300 MHz, DMSO-d6) δ 8.53 (q, J = 4.6 Hz, 1H, H24), 8.48 (s, 1H, H8), 8.43 (t, J = 1.9 Hz, 
1H, H12), 8.38 (d, J = 10.1 Hz, 2H, H18 & H20), 8.32 (dt, J = 7.6, 1.2 Hz, 1H, H16), 8.09–
7.98 (m, 3H, (H1, H17 & H21)), 7.90 (dt, J = 7.8, 1.5 Hz, 1H, H14), 7.83 (t, J = 7.7 Hz, 1H, 
H15), 2.87 (s, 3H, H30), 2.83 (d, J = 4.5 Hz, 3H, H25). 
13C NMR (101 MHz, CDCl3) δ 
167.48, 150.92, 147.61, 133.87, 130.11, 129.45, 127.33 (2C), 126.63 (2C), 126.41, 125.61 
(2C), 125.05 (2C), 122.09, 115.69, 77.24, 76.93, 44.09, 26.77. LC-MS, ESI/APCI: m/z [M + 
H]
+
 = 391.1, tr = 3.50 min. Purity = 97 %. 
(3-Hydroxyazetidin-1-yl)(4-(6-(3-(methylsulfinyl)phenyl)imidazo[1,2-b]pyridazin-3-
yl)phenyl)methanone 67. 
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Yellow solid (0.0249 g, 13 %); m.p. 248–250 °C; Rf = 0.23 (4 % MeOH/DCM); 1H NMR 
(400 MHz, CDCl3) δ 8.32–8.30 (br s, 1H, H16 ), 8.20 (d, J = 8.5 Hz, 2H, H18 & H20) 8.17–
8.11 (m, 3H, (H6, H12, & H8)), 7.79 (d, J = 8.5 Hz, 2H, H17 & H21), 7.75–7.69 (m, 2H, 
H13 & H14), 7.65 (d, J = 9.5 Hz, 2H, H1), 4.82–4.71 (m, 1H, H29), 4.64–4.47 (br s, 2H, 
H28b & H30b), 4.23 (d, J = 57.9 Hz, 2H, H28a & H30a), 2.83 (s, 3H, H27). 
13
C NMR (101 
MHz, CDCl3) δ 169.79, 150.53, 147.08, 137.06, 134.19, 132.37, 131.09 (2C), 130.23, 
129.61, 128.41 (2C), 126.49 (2C), 126.39, 125.07, 122.06 (3C), 115.70, 61.97, 44.05, 29.68. 
LC-MS, ESI/APCI: m/z [M + H]
+
 = 433.1, tr = 3.29 min. Purity = 96 %. 
N,N-Dimethyl-4-(6-(3-(methylsulfinyl)phenyl)imidazo[1,2-b]pyridazin-3-yl)benzamide 63. 
 
Yellow oil (0.0285 g, 24 %); m.p. ND; Rf = 0.69 (5 % MeOH/DCM); 
1
H NMR (300 MHz, 
DMSO-d6) δ 8.43–8.41 (m, 2H, H8 & H16), 8.38–8.30 (m, 4H, (H18, H20, H6 & H12), 8.00 
(d, J = 9.5 Hz, 1H, H1), 7.89 (dt, J = 7.7, 2.35 Hz, 1H, H14), 7.82 (t, J = 7.7 Hz, 1H, H13), 
7.60 (d, J = 8.2 Hz, 2H, H17 & H21), 3.06–2.97 (br s, 6H, H29 & H33), 2.86 (s, 3H, H27). 
13
C NMR (101 MHz, CDCl3) δ 171.17, 150.46, 147.25, 137.15, 135.79, 130.21, 129.62 (3C), 
127.68 (3C), 126.64, 125.01 (2C), 122.05, 115.61, 44.15, 29.68 (2C). LC-MS, ESI/APCI: m/z 
[M + H]
+
 = 405.1, tr = 3.58 min. Purity = 98 %. 
 
108 
Luyanda Centani – MSc Thesis, Univeristy of Cape Town, 2018   
(4-(6-(3-(Methylsulfinyl)phenyl)imidazo[1,2-b]pyridazin-3-
yl)phenyl)(morpholino)methanone 66. 
 
Yellow solid (0.0653 g, 47 %); m.p. 248.3–250.3 °C; Rf = 0.43 (5 % MeOH/DCM); 1H NMR 
(400 MHz, CDCl3) δ 8.48–8.33 (br, 1H, H16), 8.35 (s, 1H, H8), 8.23–8.17 (m, 4H, (H12, H6, 
H20 & H18)), 7.86–7.71 (m, 3H, (H1, H13 & H14))), 7.64 (d, J = 8.2 Hz, 2H, H21 & H17), 
3.88–3.58 (br m, 8H,(H29, H30, H32 &H33)), 2.84 (s, 3H, H27). 13C NMR (101 MHz, 
CDCl3) δ 169.95, 150.87, 147.34, 136.99 (2C), 134.86, 130.23, 129.62, 127.79 (3C), 126.86 
(2C), 126.74, 126.45, 125.15, 122.10 (2C), 116.10, 67.10 (2C), 66.93 (2C), 44.12. LC-MS, 
ESI/APCI: m/z [M + H]
+
 = 447.1, tr = 3.48 min. Purity = 100 %. 
(3-Hydroxypyrrolidin-1-yl)(4-(6-(3-(methylsulfinyl)phenyl)imidazo[1,2-b]pyridazin-3-
yl)phenyl)methanone 68. 
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Yellow solid (0.0280 g, 20 %); m.p. ND; Rf = 0.55 (5 % MeOH/DCM); 
1
H NMR (300 MHz, 
Methanol-d4) δ 8.49 (t, J = 1.1 Hz, 1H, H16), 8.41–8.31 (m, 3H, (H18, H20, & H8)), 8.30–
8.21 (m, 2H, H6 & H12), 7.96 (d, J = 9.4 Hz, 1H), 7.89 (dt, J = 7.5, 1.9 Hz, 1H, H14), 7.84 
(t, J = 8.5 Hz, 1H, H13), 7.76 (d, J = 7.8 Hz, 2H, H21 & H17), 4.57–4.50 (m, 1H, H33), 
4.46–4.39 (m, 1H, H31), 3.89–3.71 [m, 3H, (H29b, H30b, H32b)], 2.91 (s, 3H, H27), 2.23–
1.87 (m, 3H, H29a, H30a, H32a). 
13C NMR (101 MHz, CDCl3) δ 169.57, 150.58, 150.39, 
147.14, 137.05, 136.28, 133.85, 133.62, 130.16, 129.61, 129.50, 127.84, 127.74 (2C), 126.74 
(2C), 126.46, 125.06, 122.04, 115.70, 53.40, 44.07, 29.68, 22.67. LC-MS, ESI/APCI: m/z [M 
+ H]
+
 = 447.1, tr = 3.28 min. Purity = 100 %. 
(4-(6-(3-(Methylsulfinyl)phenyl)imidazo[1,2-b]pyridazin-3-yl)phenyl)(piperidin-1-
yl)methanone 65. 
 
Yellow solid (0.0468 g, 27 %); m.p. 268.4–270.4 °C; Rf = 0.39 (5 % MeOH/DCM); 1H NMR 
(600 MHz, Methanol-d4) δ 8.42 (t, J = 1.8 Hz, 1H, H16), 8.29 (d, J = 8.4 Hz, 2H, H18 & 
H20), 8.26 (dt, J = 1.8, 1.53 Hz, 1H, H12), 8.20 (s, 1H, H8), 8.16 (d, J = 9.5 Hz, 1H, H6), 
7.87 (d, J = 9.5 Hz, 1H, H1), 7.83 (dt, J = 7.9, 1.3 Hz, 1H, H14), 7.76 (t, J = 7.8 Hz, 1H, 
H13), 7.57 (d, J = 8.1 Hz, 2H, H17 & H21), 3.79–3.68 (m, 2H, H30a & H34a), 3.51–3.39 (m, 
2H, H30b & H34b), 2.87 (s, 3H, H27), 1.77–1.52 [m, 6H, (H31, H32, H33)]. 13C NMR (151 
MHz, MeOD) δ 171.9, 152.3, 147.6, 141.1, 138.2, 136.8, 134.2, 131.5, 131.1, 131.0, 129.4, 
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128.4 (2C), 127.9 (2C), 127.0, 126.5, 123.4, 117.9, 50.2, 44.4, 43.7, 27.6, 26.8, 25.5. 
ESI/APCI: m/z [M + H]
+
 = 444.7, tr = 4.11 min. Purity = 97 %. 
 (4-(6-(3-(Methylsulfinyl)phenyl)imidazo[1,2-b]pyridazin-3-yl)phenyl)(piperazin-1-
yl)methanone 70. 
 
18.1 mg (0.033 mmol) of boc-protected precursor was dissolved in 2 ml of DCM (in an ice 
bath) and 0.2 ml (2.6 mmol) of trifluoroacetic acid (TFA) was added dropwise, in small 
portions, over 30 mins. The reaction was allowed to proceed until completion (LCMS, 90 
mins) to remove boc. TFA was removed in vacuo, the residue was dissolved in 10 ml 10 % 
MeOH/DCM and neutralised using Amberlyst A21 for 90 mins. Compound was obtained 
after prep TLC in 10 % MeOH/DCM. 
Yellow solid (0.0160 g, 5 %); m.p. ND; Rf = 0.14 (5 % MeOH/DCM); LC-MS, ESI/APCI: 
m/z [M + H]
+
 = 446.1, tr = 2.65 min. Purity = 96 %. 
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(4-Hydroxypiperidin-1-yl)(4-(6-(3-(methylsulfinyl)phenyl)imidazo[1,2-b]pyridazin-3-
yl)phenyl)methanone 69. 
 
Yellow solid (0.0127g, 9 %); m.p. ND; Rf = 0.41 (5 % MeOH/DCM); LC-MS, ESI/APCI: 
m/z [M + H]
+
 = 460.16, tr = 3.36 min. Purity = 99 %. 
6.2.5 General procedure for Suzuki-Miyaura coupling at 80 °C and 100 °C of 
compounds 75 and 76. 
A similar method described in 6.2.3 was followed but with slight modification. First and 
second Suzuki-Miyaura coupling reactions were done in 1,4-dioxane instead of using DMF. 
A residue obtained after removing 1,4-dioxane in vacuo was washed with saturated NaCl and 
DCM. 75 was not purified and was used as is in second Suzuki-Miyaura reaction to obtain 
intermediate 76. 
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3-(3-(4-(Methylsulfinyl)phenyl)imidazo[1,2-b]pyridazin-6-yl)benzoic acid 76.  
 
Column chromatography (10 % EtOH/DCM, 5 % MeOH/DCM); yellow solid (1.263 g, 68 
%); m.p. not determined; Rf = 0.23 (10% MeOH/DCM). 
 1
H NMR (600 MHz, DMSO-d6) δ 
8.64-8.60 (br, 1H, H16), 8.46 (d, J = 8.8 Hz, 2H, H17 & H21), 8.40 (s, 1H, H8), 8.31 (d, J = 
9.5 Hz, 1H, H6), 8.25 (dt, J = 7.8, 2.0 Hz, 1H, H12), 8.08 (dt, J = 7.7, 1.9 Hz, 1H, H14), 7.92 
(d, J = 9.5 Hz, 1H, H1), 7.83 (d, J = 8.8 Hz, 2H, H18 & H20), 7.63 (t, J = 7.7 Hz, 1H, H13), 
2.80 (s, 3H, H26); 
13C NMR (151 MHz, DMSO) δ 168.33, 151.63, 145.78, 140.13, 135.43, 
134.91 (2C), 131.32, 131.19, 130.21, 129.52, 128.17, 127.94, 127.12, 127.04, 126.83, 124.59 
(2C), 116.96, 43.62. LC-MS, ESI/APCI: m/z [M + H]
+
 = 378.0, tr = 2.74 min. Purity = 94 %. 
6.2.6 General procedure for amide coupling via propylphosphonic anhydride solution ≥ 
50 wt. % in ethyl acetate to form 77-86. 
Similar approach described in 6.2.4 was followed with slight modification. Reaction was 
carried out in 1,4-dioxane instead of using DMF. Target compounds were purified with 
appropriate mobile phase (5 % EtOH/DCM, 5 % MeOH/DCM) using preparatory TLC 
plates. All compounds were triturated with hot hexane to obtain a solid material except for 84 
which remained oily.   
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N-Allyl-3-(3-(4-(methylsulfinyl)phenyl)imidazo[1,2-b]pyridazin-6-yl)benzamide 79. 
 
Yellow solid (0.0664 g, 60 %); m.p. 228.7–230.7 °C; Rf = 0.49 (10 % MeOH/DCM).  1H 
NMR (300 MHz, DMSO-d6) δ 8.88 (t, J = 5.7 Hz, 1H, H30), 8.60 (t, J = 1.5 Hz, 1H, H16), 
8.50 (d, J = 8.5 Hz, 2H, H21 & H17), 8.44 (s, 1H, H8), 8.40 (d, J = 9.5 Hz, 1H, H6), 8.32 (dt, 
J = 7.9, 2.9 Hz, 1H, H12), 8.08–7.98 (m, 2H, H14 & H1), 7.87 (d, J = 8.4 Hz, 2H, H20 & 
H18), 7.72 (t, J = 7.8 Hz, 1H, H13), 6.06–5.86 (m, 1H, H31), 5.25 (dq, J = 17.2, 1.86 Hz, 1H, 
H33), 5.15 (dq, J = 10.2, 1.7 Hz, 1H, H32), 3.99 (t, J = 5.3 Hz, 2H, H27), 2.83 (s, 3H, H26); 
13C NMR (151 MHz, DMSO) δ 166.03, 151.35, 145.81, 140.14, 135.78, 135.64, 134.97 (2C), 
131.13, 130.07, 129.84, 129.54, 127.19 (2C), 127.16, 127.07, 126.32, 124.63 (2C), 116.92, 
115.80, 43.65, 42.06; LC-MS, ESI/APCI: m/z [M + H]
+
 = 417.1, tr = 2.57 min. Purity = 99 %. 
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N-(2-Methoxyethyl)-3-(3-(4-(methylsulfinyl)phenyl)imidazo[1,2-b]pyridazin-6yl)benzamide 
78. 
 
Yellow solid (0.0491 g, 43 %); m.p. 206.3–208.3 °C Rf = 0.49 (10 % MeOH/DCM).  1H 
NMR (600 MHz, DMSO-d6) δ 8.74 (t, J = 5.15 Hz, 1H, H28), 8.56 (t, J = 1.82 Hz, 1H, H16), 
8.48 (d, J = 8.53 Hz, 2H, H17 & H21), 8.42 (s, 1H, H8), 8.38 (d, J = 9.51 Hz, 1H, H, H6), 
8.30 (dt, J = 7.80, 1.90 Hz, 1H, H12), 8.02 (dt, J = 7.79, 1.34 Hz, 1H, H14), 7.99 (d, J = 9.57 
Hz, 1H, H1), 7.86 (d, J = 8.50 Hz, 2H, H18 & H20), 7.69 (t, J = 7.75 Hz, 1H, H13), 3.52–
3.46 (m, 4H, H30 & H31), 3.29 (s, 3H, H33), 2.81 (s, 3H, H26); 
13
C NMR (151 MHz, 
DMSO) δ 166.25, 151.38, 145.82, 140.14, 135.75, 135.63, 134.98 (2C), 131.13, 130.06, 
129.80, 129.53, 127.18 (2C), 127.15, 127.07, 126.33, 124.63 (2C), 116.93, 71.01, 58.45, 
43.64.; LC-MS, ESI/APCI: m/z [M + H]
+
 = 435.1, tr = 2.93 min. Purity = 97 %. 
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N-Cyclopropyl-3-(3-(4-(methylsulfinyl)phenyl)imidazo[1,2-b]pyridazin-6-yl)benzamide 81. 
 
Yellow solid (0.0500 g, 45 %); m.p. 250.5–252.5 °C; Rf = 0.44 (10 % MeOH/DCM);  1H 
NMR (600 MHz, DMSO-d6) δ 8.62 (d, J = 4.2 Hz, 1H, H27), 8.49 (t, J = 1.8 Hz, 1H, H16), 
8.46 (d, J = 8.5 Hz, 2H, H17 & H21), 8.41 (s, 1H, H8), 8.37 (d, J = 9.3 Hz, 1H, H6 ), 8.28 
(dt, J = 7.8, 1.5 Hz, 1H, H12), 7.99–7.95 (m, 2H, H1 & H14), 7.84 (d, J = 8.6 Hz, 2H, H20 & 
H18), 7.66 (t, J = 7.8 Hz, 1H, H13), 2.92–2.86 (m, 1H, H31), 2.80 (s, 3H, H26), 0.75–0.70 
(m, 2H, H33), 0.62–0.58 (m, 2H, H32); 13C NMR (151 MHz, DMSO) δ 167.46, 151.34, 
145.83, 140.13, 135.78, 135.56, 134.96 (2C), 131.13, 129.98, 129.74, 129.44, 127.20, 127.16 
(2C), 127.06, 126.30, 124.62 (2C), 116.92, 43.64, 23.58, 6.28.; LC-MS, ESI/APCI: m/z [M + 
H]
+
 = 417.1, tr = 2.68 min. Purity = 99 %. 
 
 
 
 
 
116 
Luyanda Centani – MSc Thesis, Univeristy of Cape Town, 2018   
N-(1-Hydroxybutan-2-yl)-3-(3-(4-(methylsulfinyl)phenyl)imidazo[1,2-b]pyridazin-6-
yl)benzamide 80. 
 
Yellow solid (0.0039 g, 13 %); m.p ND; Rf = 0.35 (10 % MeOH/DCM); 
 1
H NMR (300 
MHz, DMSO-d6) δ 8.59 (t, J = 1.1 Hz, 1H, H16), 8.50 (d, J = 8.4 Hz, 2H, H17 & H21), 8.44 
(s, 1H, H8), 8.40 (d, J = 9.6 Hz, 1H, H6 ), 8.32 (dt, J = 7.9, 1.3 Hz, 1H, H12 ), 8.25 (d, J = 
8.3 Hz, 1H, H133), 8.07–8.00 (m, 2H, H14 & H1), 7.87 (d, J = 8.4 Hz, 2H, H18 & H20), 
7.70 (t, J = 7.8 Hz, 1H, H13), 4.70 (t, J = 5.7 Hz, 1H, H30), 4.01–3.87 (m, H32a ), 3.58–3.40 
(m, 1H, H32b), 2.82 (s, 3H, H26), 1.79–1.65 (m, 1H, H31a), 1.60–1.41 (m, 1H, H31b), 0.93 
(t, J = 7.4 Hz, 3H, H35); 
13C NMR (151 MHz, DMSO) δ 166.30, 151.36, 145.83, 140.14, 
136.32, 135.45, 134.98 (2C), 131.14, 129.87, 129.70, 127.21 (2C), 127.16, 127.06, 126.33, 
124.62 (2C), 116.93, 63.56, 53.69, 43.65, 24.17, 11.15; LC-MS, ESI/APCI: m/z [M + H]
+
 = 
449.1, tr = 3.45 min. Purity = 99 %. 
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N-(2-Hydroxyethyl)-3-(3-(4-(methylsulfinyl)phenyl)imidazo[1,2-b]pyridazin-6-
yl)benzamide 77. 
 
Yellow solid (0.00342 g, 4.0 %); m.p ND; Rf = 0.34 (10 % MeOH/DCM);
 1
H NMR (300 
MHz, DMSO-d6) δ 8.67 (t, J = 5.5 Hz, 1H, H30), 8.59 (t, J = 1.8 Hz, 1H, H16), 8.50 (d, J = 
8.4 Hz, 2H, H21 & H17), 8.44 (s, 1H, H8), 8.40 (d, J = 9.5 Hz, 1H, H6), 8.32 (dt, J = 7.8, 1.1 
Hz, 1H, H12), 8.07–7.97 (m, 2H, H1 & H14), 7.88 (d, J = 8.4 Hz, 2H, H18 & H20), 7.71 (t, J 
= 7.8 Hz, 1H, H13), 4.76 (t, J = 5.6 Hz, 1H, H29), 3.58 (q, J = 5.9 Hz, 2H, H27), 3.41 (q, J = 
5.8 Hz, 2H, H28), 2.83 (s, 3H, H26);
13C NMR (151 MHz, DMSO) δ 166.29, 151.39, 145.83, 
140.14, 135.92, 135.59, 134.98 (2C), 131.13, 129.96, 129.77, 129.52, 127.19 (2C), 127.16, 
127.08, 126.37, 124.64 (2C), 116.92, 60.243, 43.64, 42.78. LC-MS, ESI/APCI: m/z [M + H]
+
 
= 421.1, tr = 3.36 min. Purity = 96 %. 
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(3-(3-(4-(Methylsulfinyl)phenyl)imidazo[1,2-b]pyridazin-6-
yl)phenyl)(morpholino)methanone 84. 
 
Yellow oil (0.0606 g, 51 %); Rf = 0.51 (10 % MeOH/DCM); 
 1
H NMR (300 MHz, Methanol-
d4) δ 8.48 (d, J = 8.7 Hz, 2H, H21 & H17), 8.29 (s, 1H, H8), 8.28–8.18 (m, 3H, (H6, H12, & 
H16 )), 7.96–7.88 (m, 3H, (H1, H18, & H20)), 7.71 (t, J = 8.2 Hz, 1H, H13), 7.64 (dt, J = 7.7, 
1.5 Hz, 1H, H14), 3.89–3.60 (br m, 8H, (H27, H28, H29, & H30)), 2.90 (s, 3H, H26); 13C 
NMR (151 MHz, DMSO) δ 168.97, 151.26, 145.88, 140.13, 136.97, 135.77, 134.98 (2C), 
131.14, 129.98, 129.29, 128.65, 127.19 (2C), 127.05, 126.04, 124.61 (2C), 117.02, 66.56 
(2C), 43.66, 40.55 (2C). LC-MS, ESI/APCI: m/z [M + H]
+
 = 447.1, tr = 2.61 min. Purity = 97 
%. 
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(3-(3-(4-(Methylsulfinyl)phenyl)imidazo[1,2-b]pyridazin-6-yl)phenyl)(piperidin-1-
yl)methanone 85. 
 
Yellow solid (0.0422 g, 36 %); m.p. 256.4–258.4 °C; Rf = 0.53 (10 % MeOH/DCM);  1H 
NMR (300 MHz, Methanol-d4) δ 8.48 (d, J = 8.4 Hz, 2H, (H17 & H21)), 8.29 (s, 1H, H8), 
8.26–8.13 (m, 3H, (H6, H16, & H12)), 7.97–7.85 (m, 3H, (H18, H20, & H1)), 7.70 (t, J = 7.7 
Hz, 1H, H13), 7.60 (dt, J = 7.7, 1.00 Hz, 1H, H14), 3.86–3.70 (br m, 2H, H27e & H31e), 
3.53–3.40 (br m, 2H, H27a & H31a), 2.90 (s, 3H, H26), 1.81–1.54 (br m, 6H, (H28, H29, & 
H30)); 
13C NMR (151 MHz, MeOD) δ 170.16, 151.63, 143.96, 139.97, 137.00, 135.77 (2C), 
133.10, 131.51, 129.29, 128.20, 128.18, 127.57, 127.32, 125.64, 125.11, 123.99 (2C), 116.98, 
48.74, 43.05, 42.15, 26.25, 25.36, 24.04. LC-MS, ESI/APCI: m/z [M + H]
+
 = 445.1, tr = 2.69 
min. Purity = 98 %. 
N-Methyl-3-(3-(4-(methylsulfinyl)phenyl)imidazo[1,2-b]pyridazin-6-yl)benzamide 83. 
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Yellow solid (0.0196 g, 18 %); m.p. 256.1–258.1°C; Rf = 0.40 (10 % MeOH/DCM);  1H 
NMR (300 MHz, DMSO-d6) δ 8.64 (q, J = 5.1 Hz, 1H, H27), 8.54 (t, J = 2.0 Hz, 1H, H16), 
8.48 (d, J = 8.6 Hz, 2H, H17 & H21), 8.44 (s, 1H, H8), 8.39 (d, J = 9.5 Hz, 1H, H6), 8.31 (dt, 
J = 7.8, 1.6 Hz, 1H, H12), 8.05–7.94 (m, 2H, H1 & H14), 7.87 (d, J = 8.4 Hz, 2H, H18 & 
H20), 7.70 (t, J = 7.8 Hz, 1H, H13), 2.86 (d, J = 4.5 Hz, 3H, H28), 2.83 (s, 3H, H6); 
13
C 
NMR (151 MHz, DMSO) δ 166.58, 151.44, 145.82, 140.13, 135.85, 135.70, 134.98 (2C), 
131.13, 129.97, 129.82, 129.29, 127.18 (2C), 127.09, 126.27, 124.64 (2C), 116.94, 43.63, 
26.79. LC-MS, ESI/APCI: m/z [M + H]
+
 = 391.1, tr = 2.46 min. Purity = 96 %. 
N,N-Dimethyl-3-(3-(4-(methylsulfinyl)phenyl)imidazo[1,2-b]pyridazin-6-yl)benzamide 82. 
 
Yellow solid (0.0112 g, 10 %); m.p ND; Rf = 0.48 (10 % MeOH/DCM); 
 1
H NMR (300 
MHz, DMSO-d6) δ 8.52–8.38 (m, 3H, (H16, H21, & H17)), 8.33 (d, J = 9.4 Hz, 1H, H6), 
8.21 (dt, J = 7.4, 3.2 Hz, 1H, H12), 8.13 (s, 1H, H8), 7.95 (d, J = 9.5 Hz, 1H, H1), 7.86 (d, J 
= 8.0 Hz, 2H, H20 & H18), 7.74–7.53 (m, 2H, H13 & H14), 3.14–2.92 (br s, 6H, H28 & 
H29), 2.83 (s, 3H, H26); 
13C NMR (151 MHz, DMSO) δ 169.96, 151.35, 145.81, 140.11, 
137.81, 135.63, 134.94 (2C), 131.13, 129.76, 129.20, 128.42, 127.16, 127.13, 127.01, 126.05, 
124.59 (2C), 117.00, 43.633, 35.33 (2C); LC-MS, ESI/APCI: m/z [M + H]
+
 = 405.1, tr = 2.49 
min. Purity = 97 %. 
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N-(4-Methoxycyclohexyl)-3-(3-(4-(methylsulfinyl)phenyl)imidazo[1,2-b]pyridazin-6-
yl)benzamide 86. 
 
Yellow solid (0.0589 g, 45 %); m.p 308.4–310.4 °C; Rf = 0.65 (10 % MeOH/DCM); 1H 
NMR (300 MHz, DMSO-d6) δ 8.55 (t, J = 1.8 Hz, 1H, H16), 8.49 (d, J = 8.2 Hz, 2H, H17 & 
H21), 8.44 (s, 1H, H8), 8.39 (d, J = 9.6 Hz, 1H, H6), 8.32 (dt, J = 8.3, 0.83 Hz, 1H, H12), 
8.05–7.96 (m, 2H, H1 & H14), 7.87 (d, J = 8.1 Hz, 2H, H18 & H20), 7.69 (t, J = 7.8 Hz, 1H, 
H13), 3.93–3.74 (m, 1H, H32), 3.27 (s, 3H, H34), 3.23–3.08 (m, 1H, H33), 2.83 (s, 3H, H26), 
2.14–2.00 (m, 2H, H31e & H30e), 2.01–1.85 (m, 2H, H28e & H39e), 1.51–1.33 (m, 2H, 
H31a & H30a), 1.33–1.14 (m, 2H, H28a & H29a). 13C NMR (151 MHz, DMSO) δ 165.76, 
151.36, 146.05, 140.16, 136.40, 135.53, 134.92 (2C), 131.20, 129.80, 129.62, 129.55, 127.28 
(2C), 127.00, 126.35, 124.59 (2C), 116.83, 78.29 (2C), 55.51, 48.57, 43.75, 30.68 (2C), 
30.42. LC-MS, ESI/APCI: m/z [M + H]
+
 = 489.2, tr = 2.35 min. Purity = 95 %. 
6.3 Pharmacological assays 
6.3.1 In vitro P. falciparum asexual blood parasite stage assay 
The antiplasmodium activities of the test compounds were assessed against the CQ-sensitive 
P. falciparum strain NF54, in duplicate. Continuous in vitro cultures of P. falciparum 
parasites at the asexual erythrocyte stages were maintained following a modified version of 
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the method developed by Trager and Jensen.
88
 Quantitative assessment of the compounds’ in 
vitro antiplasmodium activities was conducted via a parasite lactate dehydrogenase assay 
using the modified method described by Makler et al. with slight modifications.
89
  
 The test compounds were suspended in 100 % DMSO to obtain stock solutions of 20 
mg/mL, which were sonicated to enhance solubility and stored at -20 °C. The stock solutions 
were further diluted on the day of the experiment. The activities of the test compounds were 
compared to those of CQ and artesunate which were used as reference compounds. A full 
dose-response analysis was performed for all compounds to determine the concentration at 
which 50 % of parasite growth was inhibited. Ten stock solutions were prepared via 2-fold 
serial dilution to obtain a 10-point dose-response curve for each compound, at concentrations 
ranging from 0.02 to 10 μg/mL. 
The starting concentration of the compounds was 1 µg/mL, with the highest concentration of 
solvent used to dissolve the compounds not affecting parasite viability. Samples were 
incubated with parasites at 37 °C for 72 h, after which cells were re-suspended. A 15 µL 
aliquot was removed and transferred to another plate containing 100 µL Malstat reagent and 
25 µL nitroblue tetrazolium and phenozine ethosulphate (Makler). The plates were incubated 
in the dark until completion of the reaction. Absorbance was then measured at 620 nm on a 
spectrophotometer. From these data, IC50 values were calculated via non-linear dose-response 
curve fitting analysis using GraphPad Prism v.4.0 software (GraphPad, San Diego, CA, 
USA). 
6.3.2 Gametocidal activity assay 
The luciferase reporter assay was established to enable accurate, reliable and quantifiable 
investigations of the stage-specific action of gametocytocidal compounds for the early and 
late 
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gametocyte marker cell line NF54-PfS16-GFP-Luc.
90
 Drug assays were set up on day 5 and 
10 
(Representing > 90 % of either early stage II/III or mature stage IV/V gametocytes, 
respectively). In each instance, assays were set up using a 2-3 % gametocytaemia, 1.5 % 
haematocrit culture and 48 h drug pressure in a gas chamber (90 % N2, 5 % O2, and 5 % 
CO2) at 37 ºC.
90
 Luciferase activity was determined in 30 µL parasite lysates by adding 30 
µL luciferin substrate (Promega Luciferase Assay System) at room temperature and detection 
of resultant bioluminescence at an integration constant of 10 s with the GloMax® Explorer 
Detection System with Instinct® Software. Methylene blue (5 µM) and internal project 
specific controls (MMV390048, 5 μM) are routinely included as controls. 
6.3.3 In vitro cytotoxicity assay  
Cytotocxicity was measured using the method described by Mosmann et al, this procedure 
uses MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide)-assay (MTT-
assay) to measure cellular growth and survival calorimetrically.
91
 All growth and 
chemosensitivity was measured by the formation of tetrazolium salt. The test samples were 
evaluated in triplicate. The test samples were dissolved in DMSO to prepare a stock solution 
of 2 mg/mL and insoluble samples were tested as suspensions. The prepared stock solution 
were stored at -20 °C until required. Emetine drug was used for calibration in all experiments. 
10-fold serial dilutions in complete medium to give 6 concentrations were made from an 
initial concentration of 100 μg/mL with the lowest concentration being 0.001 μg/mL. Though 
cells were exposed to high solvent concentration remained capable of surviving. The IC50 
values were determined from full dose-response curves plotted using a non-linear dose-
response curve fitting analysis using GraphPad Prism v.4.0 software (GraphPad, San Diego, 
CA, USA).  
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6.4 Solubility assays 
6.4.1 Preparation of of 0.01M pH 7.4 phosphate buffered saline (PBS) 
One intact PBS buffer tablet was dissolved in deionized water to make 1000 mL solution that 
is consist of 0.14M NaCl, 0.003M KCl and 0.01M phosphate buffer. The solution was passed 
through a 0.22 µM nylon filter to remove any particulate contaminants and ascertain the pH 
using a pH meter.
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6.4.2 Turbidimetric solubility procedure 
Each compound (2–3 mg) was dissolved in DMSO to prepare 10 mM stock solutions.93 
Heterogeneous solutions were mixed by vortexing until all material was dissolved. Serial 
dilutions of 1, 2, 3, and 4, ranging from 10 mM to 0 mM were prepared in a 96 well plate 
(Figure 45) in triplicate, a blank well was included as a reference.  
 
Figure 45: Pre-dilution plate layout. 
Rows B to H contain stock solutions with increasing concentrations. 
The layout of the secondary dilution plate containing compound solutions prepared in DMSO 
and 0.01 M pH 7.4 PBS, is shown in Figure 46. Columns 1 to 6 contain compound solutions 
prepared in DMSO, while columns 7 to 12 contain compound solutions in PBS.
93
 The final 
volume in each well is 200 µL (4 µL solvent from the pre-dilution plate and 196 µL DMSO 
or PBS). The assay plate was incubated for 2 h at 26 °C, after which the absorbance of the 
assay plate contents was measured at 620 nm.   
Conc (µM)
0,00 A 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00
0,25 B 0,25 0,25 0,25 0,25 0,25 0,25 0,25 0,25 0,25 0,25 0,25 0,25
0,50 C 0,50 0,50 0,50 0,50 0,50 0,50 0,50 0,50 0,50 0,50 0,50 0,50
1,00 D 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00
2,00 E 2,00 2,00 2,00 2,00 2,00 2,00 2,00 2,00 2,00 2,00 2,00 2,00
4,00 F 4,00 4,00 4,00 4,00 4,00 4,00 4,00 4,00 4,00 4,00 4,00 4,00
8,00 G 8,00 8,00 8,00 8,00 8,00 8,00 8,00 8,00 8,00 8,00 8,00 8,00
10,00 H 10,00 10,00 10,00 10,00 10,00 10,00 10,00 10,00 10,00 10,00 10,00 10,00
Compound 1 Compound 2 Compound 3 Compound 4
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Figure 46: Turbidimetric assay plate lay-out. 
The raw absorbance data were corrected by subtracting the absorbance of the blank samples 
(DMSO and 2 % DMSO in PBS) from the absorbance of the test samples. The solubility of 
the compounds was determined by plotting a graph of the corrected absorbance versus 
concentration. The solubility curves of hydrocortisone and reserpine (reference compounds) 
are shown in Figure 47 and Figure 48 respectively. The assay was considered valid if the 
DMSO graph did not deviate from the x-axis. The compound solubility threshold is 
determined as the concentration the PBS graph deviates from the DMSO graph. In the given 
examples, hydrocortisone is soluble over the entire concentration range, whereas the 
solubility threshold of reserpine is approximately 10 µM. 
 
1 2 3 4 5 6 7 8 9 10 11 12
0 A
5 B
10 C
20 D
40 E
80 F
160 G
200 H
4 µL (Pipette from pre-dilution)+196 µL DMSO 4 µL (Pipette from pre-dilution)+196 µL 0,01 M pH 7,4 PBS
Conc (µM)
DMSO 0,01 M pH 7,4 PBS
Compound 1(Triplicate) Compound 2 (Triplicate) Compound 1 (Triplicate) Compound 2 (Triplicate)
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Figure 47: Solubility of hydrocortisone. 
DMSO, dimethylsulfoxide; PBS, phosphate buffered saline. 
 
Figure 48: Solubility of reserpine. 
DMSO, dimethylsulfoxide; PBS, phosphate buffered saline. 
Turbidimetric solubility results were used to rank the compounds as poorly, moderately, or 
highly soluble, following the classification listed in Table 14.
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Table 14: Turbidimetric solubility rankings 
 
 
6.4.3 HPLC-based kinetic solubility assay 
The method named HPLC-based solubility in this dissertation is a miniaturized shake flask 
method. The compounds were dissolved in DMSO to prepare 10 mM solutions, and spiked 
(1:50) into PBS at pH 7.4, in duplicate. The DMSO suspension were shook for 18 h at 25 °C, 
the solution were centrifuged, filtered and analysed using HPLC-DAD (Agilent 1200 Rapid 
Resolution HPLC with a diode array detector). Aqueous compounds’ solubility was 
determined through best fit calibration curves which were constructed using calibration 
standard.
49
   
 
 
 
 
 
 
Classification Turbidimertic 
solubility (µM) 
Poorly soluble < 1 
Moderately soluble  1 - 100 
Highly soluble > 100 
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Chapter seven 
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